BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2009;104:465-83; quiz 464, 484. [PMID: 19174807 DOI: 10.1038/ajg.2008.168] [Cited by in Crossref: 615] [Cited by in F6Publishing: 545] [Article Influence: 47.3] [Reference Citation Analysis]
Number Citing Articles
1 Kim MC, Kim SH, Koh SJ, Park JH, Yoon H. Clinical implication of radiologic complete remission on Crohn's Disease: Compared with endoscopic remission. Eur J Radiol 2022;155:110469. [PMID: 35988393 DOI: 10.1016/j.ejrad.2022.110469] [Reference Citation Analysis]
2 Sinagra E, Raimondo D, Iacopinelli SM, Rossi F, Conoscenti G, Di Maggio MA, Testai S, Alloro R, Marasà M, Calandra A, Costanza C, Cristofalo S, Pallio S, Maida M, Tarantino I, Arena G. An Unusual Presentation of Crohn's Disease Diagnosed Following Accidental Ingestion of Fruit Pits: Report of Two Cases and Review of the Literature. Life (Basel) 2021;11:1415. [PMID: 34947946 DOI: 10.3390/life11121415] [Reference Citation Analysis]
3 Villarreal-Leal RA, Healey GD, Corradetti B. Biomimetic immunomodulation strategies for effective tissue repair and restoration. Adv Drug Deliv Rev 2021;179:113913. [PMID: 34371087 DOI: 10.1016/j.addr.2021.113913] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
4 Hashash JG, Fadel CGA, Rimmani HH, Sharara AI. Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn's disease and ulcerative colitis. Ann Gastroenterol 2021;34:612-24. [PMID: 34475731 DOI: 10.20524/aog.2021.0645] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Banerjee R, Ali RAR, Wei SC, Adsul S. Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries. Gut Liver 2020;14:685-98. [PMID: 33191310 DOI: 10.5009/gnl19209] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
6 van Andel EM, Koopmann BDM, Crouwel F, Noomen CG, de Boer NKH, van Asseldonk DP, Mokkink LB. Systematic Review of Development and Content Validity of Patient-reported Outcome Measures in Inflammatory Bowel Disease: Do We Measure What We Measure? J Crohns Colitis 2020;14:1299-315. [PMID: 32211749 DOI: 10.1093/ecco-jcc/jjaa057] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
7 Kim B, Chae J, Kim EH, Yang HI, Cheon JH, Kim TI, Kim WH, Jeon JY, Park SJ. Physical activity and quality of life of patients with inflammatory bowel disease. Medicine (Baltimore) 2021;100:e26290. [PMID: 34232167 DOI: 10.1097/MD.0000000000026290] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Wu N, Mah C, Koentgen S, Zhang L, Grimm MC, El-Omar E, Hold GL. Inflammatory bowel disease and the gut microbiota. Proc Nutr Soc 2021;:1-11. [PMID: 34165053 DOI: 10.1017/S002966512100197X] [Reference Citation Analysis]
9 Both T, Dalm VASH, Richardson SA, van Schie N, van den Broek LM, de Vries AC, van Hagen PM, Rombach SM. Inflammatory bowel disease in primary immunodeficiency disorders is a heterogeneous clinical entity requiring an individualized treatment strategy: A systematic review. Autoimmun Rev 2021;20:102872. [PMID: 34118459 DOI: 10.1016/j.autrev.2021.102872] [Reference Citation Analysis]
10 Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing). J Dig Dis 2021;22:298-317. [PMID: 33905603 DOI: 10.1111/1751-2980.12994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zare F, Ghafari M, Ramezankhani A, Kamran BL, Kavoosi A. Identifying dimensions of empowerment in patients with inflammatory bowel disease: a qualitative study. Health Educ Res 2020;35:637-47. [PMID: 32995862 DOI: 10.1093/her/cyaa023] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
12 Estruch J, Johnson J, Ford S, Yoshimoto S, Mills T, Bergman P. Utility of the combined use of 3 serologic markers in the diagnosis and monitoring of chronic enteropathies in dogs. J Vet Intern Med 2021;35:1306-15. [PMID: 33960552 DOI: 10.1111/jvim.16132] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
13 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 45.0] [Reference Citation Analysis]
14 Ding Z, Patel A, Izanec J, Pericone CD, Lin JH, Baugh CW. Trends in US emergency department visits and subsequent hospital admission among patients with inflammatory bowel disease presenting with abdominal pain: a real-world study from a national emergency department sample database. J Mark Access Health Policy 2021;9:1912924. [PMID: 33968334 DOI: 10.1080/20016689.2021.1912924] [Reference Citation Analysis]
15 Marafini I, Stolfi C, Troncone E, Lolli E, Onali S, Paoluzi OA, Fantini MC, Biancone L, Calabrese E, Di Grazia A, Monteleone I, Lenti MV, Di Sabatino A, Monteleone G. A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn's Disease: A Phase II, Open-Label Study. BioDrugs 2021;35:325-36. [PMID: 33871807 DOI: 10.1007/s40259-021-00482-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Joustra V, Duijvestein M, Mookhoek A, Bemelman W, Buskens C, Koželj M, Novak G, Hindryckx P, Mostafavi N, D'Haens G. Natural History and Risk Stratification of Recurrent Crohn's Disease After Ileocolonic Resection: A Multicenter Retrospective Cohort Study. Inflamm Bowel Dis 2021:izab044. [PMID: 33783507 DOI: 10.1093/ibd/izab044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Nehra AK, Sheedy SP, Wells ML, VanBuren WM, Hansel SL, Deepak P, Lee YS, Bruining DH, Fletcher JG. Imaging Findings of Ileal Inflammation at Computed Tomography and Magnetic Resonance Enterography: What do They Mean When Ileoscopy and Biopsy are Negative? J Crohns Colitis 2020;14:455-64. [PMID: 31960900 DOI: 10.1093/ecco-jcc/jjz122] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
18 Ishida N, Miyazu T, Suzuki T, Tamura S, Tani S, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Furuta T, Sugimoto K. Evaluation of the modified Crohn's disease activity index in patients with Crohn disease with enterostomy: A single-center observational study. Medicine (Baltimore) 2021;100:e24717. [PMID: 33578614 DOI: 10.1097/MD.0000000000024717] [Reference Citation Analysis]
19 Garcia LC, Vale ECSD, Ferrari ML, Faria LDC. Gummatous cutaneous tuberculosis associated with the use of infliximab for Crohn's disease. An Bras Dermatol 2021;96:228-30. [PMID: 33593700 DOI: 10.1016/j.abd.2020.07.008] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Regev S, Odes S, Slonim-Nevo V, Goren G, Friger M, Greenberg D, Vardi H, Schwartz D, Sergienko R, Sarid O. Normative data for the Brief Symptom Inventory for patients with Crohn's disease. Psychol Health 2021;:1-12. [PMID: 33410712 DOI: 10.1080/08870446.2020.1862841] [Reference Citation Analysis]
21 Wu Y, Li Z, Zhao YS, Huang YY, Jiang MY, Luo HB. Therapeutic targets and potential agents for the treatment of COVID-19. Med Res Rev 2021;41:1775-97. [PMID: 33393116 DOI: 10.1002/med.21776] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
22 Shi H, Zhao X, Gao J, Liu Z, Liu Z, Wang K, Jiang J. Acid-resistant ROS-responsive hyperbranched polythioether micelles for ulcerative colitis therapy. Chinese Chemical Letters 2020;31:3102-6. [DOI: 10.1016/j.cclet.2020.03.039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
23 Nakase H. Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease. Gut Liver 2020;14:7-19. [PMID: 30919602 DOI: 10.5009/gnl18203] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
24 Miyajima S, Ishii T, Watanabe M, Ueki T, Tanaka M. Risk factors for urolithiasis in patients with Crohn's disease. Int J Urol 2021;28:220-4. [PMID: 33191551 DOI: 10.1111/iju.14442] [Reference Citation Analysis]
25 Reinisch W, Gecse K, Halfvarson J, Irving PM, Jahnsen J, Peyrin-Biroulet L, Rogler G, Schreiber S, Danese S. Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. Inflamm Bowel Dis 2021;27:106-22. [PMID: 32634212 DOI: 10.1093/ibd/izaa078] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
26 Perl D, Waljee AK, Bishu S, Higgins PDR, Wasnik AP, Stidham RW. Imaging Features Associated With Failure of Nonoperative Management of Intraabdominal Abscesses in Crohn Disease. Inflamm Bowel Dis 2019;25:1939-44. [PMID: 31294779 DOI: 10.1093/ibd/izz069] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
27 Litz C, Danielson PD, Wilsey M, Chandler NM. Impact of Magnetic Resonance Imaging in Management of Pediatric Crohn's Disease. The American Surgeon 2013;79:672-5. [DOI: 10.1177/000313481307900709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 de Campos RJDS, Lucchetti G, Lucchetti ALG, da Rocha Ribeiro TC, Chebli LA, Malaguti C, Gaburri PD, Pereira LMN, de Almeida JG, Chebli JMF. The Impact of Spirituality and Religiosity on Mental Health and Quality of Life of Patients with Active Crohn's Disease. J Relig Health 2020;59:1273-86. [PMID: 30911874 DOI: 10.1007/s10943-019-00801-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
29 Levin A, Risto A, Myrelid P. The changing landscape of surgery for Crohn's disease. Seminars in Colon and Rectal Surgery 2020;31:100740. [DOI: 10.1016/j.scrs.2020.100740] [Reference Citation Analysis]
30 Cucchiara S, D'Arcangelo G, Isoldi S, Aloi M, Stronati L. Mucosal healing in Crohn's disease: new insights. Expert Rev Gastroenterol Hepatol. 2020;14:335-345. [PMID: 32315209 DOI: 10.1080/17474124.2020.1759416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
31 Oliveira MC, Elias JB, Moraes DA, Simões BP, Rodrigues M, Ribeiro AAF, Piron-Ruiz L, Ruiz MA, Hamerschlak N. A review of hematopoietic stem cell transplantation for autoimmune diseases: multiple sclerosis, systemic sclerosis and Crohn's disease. Position paper of the Brazilian Society of Bone Marrow Transplantation. Hematol Transfus Cell Ther 2021;43:65-86. [PMID: 32418777 DOI: 10.1016/j.htct.2020.03.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
32 Zapater P, Almenara S, Gutiérrez A, Sempere L, García M, Laveda R, Martínez A, Scharl M, Cameo JI, Linares R, González-Navajas JM, Wiest R, Rogler G, Francés R. Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease. Inflamm Bowel Dis 2019;25:1357-66. [PMID: 30776076 DOI: 10.1093/ibd/izz012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
33 Gong P, Song P, Kolbe AB, Sheedy SP, Huang C, Ling W, Yu Y, Zhou C, Lok UW, Tang S, Bruining DH, Knudsen JM, Chen S. Quantitative Inflammation Assessment for Crohn Disease Using Ultrasensitive Ultrasound Microvessel Imaging: A Pilot Study. J Ultrasound Med 2020;39:1819-27. [PMID: 32297357 DOI: 10.1002/jum.15290] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
34 Gwon Y, Mo M, Chen MH, Chi Z, Li J, Xia AH, Ibrahim JG. Network meta-regression for ordinal outcomes: Applications in comparing Crohn's disease treatments. Stat Med 2020. [PMID: 32166784 DOI: 10.1002/sim.8518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Muñiz Pedrogo DA, Chen J, Hillmann B, Jeraldo P, Al-Ghalith G, Taneja V, Davis JM, Knights D, Nelson H, Faubion WA, Raffals L, Kashyap PC. An Increased Abundance of Clostridiaceae Characterizes Arthritis in Inflammatory Bowel Disease and Rheumatoid Arthritis: A Cross-sectional Study. Inflamm Bowel Dis 2019;25:902-13. [PMID: 30321331 DOI: 10.1093/ibd/izy318] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 14.0] [Reference Citation Analysis]
36 Lage AC, Oliveira CC, Batalha APDB, Araújo AF, Czuber-dochan W, Chebli JMF, Cabral LA, Malaguti C. THE INFLAMMATORY BOWEL DISEASE-FATIGUE PATIENT SELF-ASSESSMENT SCALE: TRANSLATION, CROSS-CULTURAL ADAPTATION AND PSYCHOMETRIC PROPERTIES OF THE BRAZILIAN VERSION (IBD-F BRAZIL). Arq Gastroenterol 2020;57:50-63. [DOI: 10.1590/s0004-2803.202000000-10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Luo X, Song H, Yang J, Han B, Feng Y, Leng Y, Chen Z. Encapsulation of Escherichia coli strain Nissle 1917 in a chitosan-alginate matrix by combining layer-by-layer assembly with CaCl2 cross-linking for an effective treatment of inflammatory bowel diseases. Colloids Surf B Biointerfaces 2020;189:110818. [PMID: 32018138 DOI: 10.1016/j.colsurfb.2020.110818] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
38 Wu J, Lubman DM, Kugathasan S, Denson LA, Hyams JS, Dubinsky MC, Griffiths AM, Baldassano RN, Noe JD, Rabizadeh S, Gulati AS, Rosh JR, Crandall WV, Higgins PDR, Stidham RW. Serum Protein Biomarkers of Fibrosis Aid in Risk Stratification of Future Stricturing Complications in Pediatric Crohn's Disease. Am J Gastroenterol 2019;114:777-85. [PMID: 31058681 DOI: 10.14309/ajg.0000000000000237] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
39 Takahashi N, Kitazawa C, Itani Y, Awaga Y, Hama A, Hayashi I, Takamatsu H. Exploratory clinical characterization of experimentally-induced ulcerative colitis nonhuman primates. Heliyon 2020;6:e03178. [PMID: 31938753 DOI: 10.1016/j.heliyon.2020.e03178] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Chhibba T, Ma C. Is there room for immunomodulators in ulcerative colitis? Expert Opin Biol Ther 2020;20:379-90. [PMID: 31874578 DOI: 10.1080/14712598.2020.1708896] [Reference Citation Analysis]
41 Imperatore N, Castiglione F, Testa A, De Palma GD, Caporaso N, Cassese G, Rispo A. Augmented Endoscopy for Surveillance of Colonic Inflammatory Bowel Disease: Systematic Review With Network Meta-analysis. J Crohns Colitis. 2019;13:714-724. [PMID: 30597029 DOI: 10.1093/ecco-jcc/jjy218] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
42 Delday M, Mulder I, Logan ET, Grant G. Bacteroides thetaiotaomicron Ameliorates Colon Inflammation in Preclinical Models of Crohn's Disease. Inflamm Bowel Dis 2019;25:85-96. [PMID: 30215718 DOI: 10.1093/ibd/izy281] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 20.3] [Reference Citation Analysis]
43 Chinem ESS, Esberard BC, Moreira ADL, Barbassa TG, da Cunha GM, Carneiro AJV, de Souza HS, Carvalho ATP. Changes in the Management of Patients with Crohn's Disease Based on Magnetic Resonance Enterography Patterns. Gastroenterol Res Pract. 2019;2019:3467316. [PMID: 31933630 DOI: 10.1155/2019/3467316] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
44 Ferreira TMR, Albuquerque A, Cancela Penna FG, Macedo Rosa R, Correia MITD, Barbosa AJA, Salles Cunha A, Ferrari MLA. Effect of Oral Nutrition Supplements and TGF-β2 on Nutrition and Inflammatory Patterns in Patients With Active Crohn's Disease. Nutr Clin Pract 2020;35:885-93. [PMID: 31840323 DOI: 10.1002/ncp.10448] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
45 Molander P, Kemppainen H, Ilus T, Sipponen T. Long-term deep remission during maintenance therapy with biological agents in inflammatory bowel diseases. Scand J Gastroenterol 2020;55:34-40. [PMID: 31841064 DOI: 10.1080/00365521.2019.1701070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
46 Cross RK, Chiorean M, Vekeman F, Xiao Y, Wu E, Chao J, Wang AW. Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system. PLoS One 2019;14:e0225572. [PMID: 31800627 DOI: 10.1371/journal.pone.0225572] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
47 Rapa SF, Waltenberger B, Di Paola R, Adesso S, Siracusa R, Peritore AF, D'Amico R, Autore G, Cuzzocrea S, Stuppner H, Marzocco S. Plumericin prevents intestinal inflammation and oxidative stress in vitro and in vivo. FASEB J 2020;34:1576-90. [PMID: 31914614 DOI: 10.1096/fj.201902040R] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
48 Abbass M, Cepek J, Parker CE, Nguyen TM, MacDonald JK, Feagan BG, Khanna R, Jairath V. Adalimumab for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2019;2019. [PMID: 31742665 DOI: 10.1002/14651858.CD012878.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
49 Long GH, Tatro AR, Oh YS, Reddy SR, Ananthakrishnan AN. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data. Adv Ther 2019;36:3079-95. [PMID: 31562607 DOI: 10.1007/s12325-019-01095-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
50 García-Sanjuán S, Lillo-Crespo M, Cabañero-Martínez MJ, Richart-Martínez M, Sanjuan-Quiles Á. Experiencing the care of a family member with Crohn's disease: a qualitative study. BMJ Open 2019;9:e030625. [PMID: 31641000 DOI: 10.1136/bmjopen-2019-030625] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
51 Goyal P, Shah J, Gupta S, Gupta P, Sharma V. Imaging in discriminating intestinal tuberculosis and Crohn’s disease: past, present and the future. Expert Review of Gastroenterology & Hepatology 2019;13:995-1007. [DOI: 10.1080/17474124.2019.1673730] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
52 Kim J, Kim SH, Kim TO. Evaluation of CT enterography findings for endoscopic complete remission after anti-TNF-α therapy in patients with Crohn's disease. Acta Radiol 2019;60:1200-8. [PMID: 30628841 DOI: 10.1177/0284185118820062] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Eichele DD, Young R. Medical Management of Inflammatory Bowel Disease. Surg Clin North Am 2019;99:1223-35. [PMID: 31676060 DOI: 10.1016/j.suc.2019.08.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
54 Elia J, Kane S. Adult Inflammatory Bowel Disease, Physical Rehabilitation, and Structured Exercise. Inflamm Bowel Dis. 2018;24:2543-2549. [PMID: 29850914 DOI: 10.1093/ibd/izy199] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
55 Lambrou T, Chaudhry NA, Grajo JR, Moser P, Riverso M, Mramba LK, Zimmermann EM. Small bowel stricture is associated with abnormal motility on the cine MRI sequence in patients with Crohn’s disease. European Journal of Radiology 2019;118:264-70. [DOI: 10.1016/j.ejrad.2019.08.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
56 Ng SC, Hilmi IN, Blake A, Bhayat F, Adsul S, Khan QR, Wu DC. Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting.Inflamm Bowel Dis. 2018;24:2431-2441. [PMID: 30312414 DOI: 10.1093/ibd/izy153] [Cited by in Crossref: 61] [Cited by in F6Publishing: 47] [Article Influence: 20.3] [Reference Citation Analysis]
57 Ramos GP, Stroh G, Al-Bawardy B, Faubion WA, Papadakis KA, Escalante P. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy. Inflamm Bowel Dis 2018;24:2272-7. [PMID: 29718223 DOI: 10.1093/ibd/izy133] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
58 Hansel SL, McCurdy JD, Barlow JM, Fidler J, Fletcher JG, Becker B, Prabhu NC, Faubion WA, Hanson KA, Kane SV, Kisiel JB, Loftus EV, Papadakis KA, Pardi DS, Raffals LE, Schoenoff S, Tremaine WJ, Bruining DH. Clinical Benefit of Capsule Endoscopy in Crohn's Disease: Impact on Patient Management and Prevalence of Proximal Small Bowel Involvement. Inflamm Bowel Dis. 2018;24:1582-1588. [PMID: 29788055 DOI: 10.1093/ibd/izy050] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
59 Meyer C, Bowers A, Heavener TE, Checketts JX, Vassar M. From clinical practice guideline development to trial registration: A systematic investigation of research pipeline for inflammatory bowel disease. Indian J Gastroenterol 2019;38:247-62. [PMID: 31270778 DOI: 10.1007/s12664-019-00965-4] [Reference Citation Analysis]
60 Cioffi I, Marra M, Imperatore N, Pagano MC, Santarpia L, Alfonsi L, Testa A, Sammarco R, Contaldo F, Castiglione F, Pasanisi F. Assessment of bioelectrical phase angle as a predictor of nutritional status in patients with Crohn's disease: A cross sectional study.Clin Nutr. 2020;39:1564-1571. [PMID: 31303525 DOI: 10.1016/j.clnu.2019.06.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
61 Afzali A. Inflammatory bowel disease during pregnancy: management of a disease flare or remission. Current Opinion in Gastroenterology 2019;35:281-7. [DOI: 10.1097/mog.0000000000000541] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
62 Heshmati K, Lo T, Tavakkoli A, Sheu E. Short-Term Outcomes of Inflammatory Bowel Disease after Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy. Journal of the American College of Surgeons 2019;228:893-901.e1. [DOI: 10.1016/j.jamcollsurg.2019.01.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
63 Azzman N. Crohn's Disease: Potential Drugs for Modulation of Autophagy. Medicina (Kaunas) 2019;55:E224. [PMID: 31146413 DOI: 10.3390/medicina55060224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
64 Christensen B, Colman RJ, Micic D, Gibson PR, Goeppinger SR, Yarur A, Weber CR, Cohen RD, Rubin DT. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflamm Bowel Dis 2018;24:849-60. [PMID: 29562271 DOI: 10.1093/ibd/izx067] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
65 Reinglas J, Bessissow T. Strictures in Crohn's Disease and Ulcerative Colitis: Is There a Role for the Gastroenterologist or Do We Always Need a Surgeon? Gastrointest Endosc Clin N Am 2019;29:549-62. [PMID: 31078252 DOI: 10.1016/j.giec.2019.02.009] [Reference Citation Analysis]
66 Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Safdi M, Popp JW Jr, Langholff W, Sandborn WJ. Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience. Inflamm Bowel Dis 2018;24:490-501. [PMID: 29462395 DOI: 10.1093/ibd/izx072] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 18.0] [Reference Citation Analysis]
67 Kim D, Taleban S. A Comprehensive Review of the Diagnosis and Pharmacological Management of Crohn's Disease in the Elderly Population. Drugs Aging 2019;36:607-24. [PMID: 31055789 DOI: 10.1007/s40266-019-00672-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
68 Lai H, Wang K, Dong Q, Zhu X, Li X, Qi S. Traditional Chinese medicine for management of recurrent and refractory Crohn disease: A case report. Medicine (Baltimore) 2019;98:e15148. [PMID: 30985690 DOI: 10.1097/MD.0000000000015148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
69 Stavsky J, Maitra R. The Synergistic Role of Diet and Exercise in the Prevention, Pathogenesis, and Management of Ulcerative Colitis: An Underlying Metabolic Mechanism. Nutr Metab Insights 2019;12:1178638819834526. [PMID: 30911221 DOI: 10.1177/1178638819834526] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
70 Chung EK, Lee JH, Jang DK, Lee SH, Lee JH, Park BJ, Kwon K, Lee JK. Causative Agents of Drug-Induced Pancreatitis: A Nationwide Assessment. Pancreas 2018;47:1328-36. [PMID: 30308533 DOI: 10.1097/MPA.0000000000001152] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
71 Damião AOMC, Azevedo MFC, Carlos AS, Wada MY, Silva TVM, Feitosa FC. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review. World J Gastroenterol 2019; 25(9): 1142-1157 [PMID: 30863001 DOI: 10.3748/wjg.v25.i9.1142] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 36] [Article Influence: 13.3] [Reference Citation Analysis]
72 Mahfouz M, Martin P, Carrion AF. Hepatic Complications of Inflammatory Bowel Disease. Clin Liver Dis. 2019;23:191-208. [PMID: 30947871 DOI: 10.1016/j.cld.2018.12.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
73 Sahin M, Bobusoglu O, Yetim A, Ates F. Paraoxonase-1 and arylesterase levels in patients with ulcerative colitis. Arab J Gastroenterol 2019;20:14-8. [PMID: 30745012 DOI: 10.1016/j.ajg.2019.01.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
74 Han M, Jung YS, Cheon JH, Park S. Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases. J Gastroenterol Hepatol 2019;34:1166-74. [PMID: 30672608 DOI: 10.1111/jgh.14609] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
75 Alzahrani T, Nuqali A, Naser N, Jariwala AR. Adalimumab-induced acute myeloid leukaemia in a patient with Crohn's disease. BMJ Case Rep 2019;12:bcr-2018-225680. [PMID: 30718264 DOI: 10.1136/bcr-2018-225680] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
76 Ghosh S, Bressler B, Petkau J, Thakkar RB, Wang S, Skup M, Chao J, Panaccione R, Schreiber S. Healthcare Providers Underestimate Patients’ Glucocorticoid Use in Crohn’s Disease. Dig Dis Sci 2019;64:1142-9. [DOI: 10.1007/s10620-018-5419-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
77 Dumic I, Nordin T, Jecmenica M, Stojkovic Lalosevic M, Milosavljevic T, Milovanovic T. Gastrointestinal Tract Disorders in Older Age. Can J Gastroenterol Hepatol 2019;2019:6757524. [PMID: 30792972 DOI: 10.1155/2019/6757524] [Cited by in Crossref: 73] [Cited by in F6Publishing: 53] [Article Influence: 24.3] [Reference Citation Analysis]
78 Hubbard Y, Rizzolo D. What every PA needs to know about anorectal pain. JAAPA 2019;32:1-7. [PMID: 30589743 DOI: 10.1097/01.JAA.0000550292.01522.48] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
79 Aliyev ER, Hay JW, Hwang C. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients. Pharmacotherapy 2019;39:118-28. [PMID: 30565265 DOI: 10.1002/phar.2208] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
80 Na SY, Moon W. [Evolving Therapeutic Strategies in the Inflammatory Bowel Disease]. Korean J Gastroenterol 2018;71:61-8. [PMID: 29471602 DOI: 10.4166/kjg.2018.71.2.61] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
81 da Silva VC, de Araújo AA, de Souza Araújo DF, Souza Lima MCJ, Vasconcelos RC, de Araújo Júnior RF, Langasnner SMZ, de Freitas Fernandes Pedrosa M, de Medeiros CACX, Guerra GCB. Intestinal Anti-Inflammatory Activity of the Aqueous Extract from Ipomoea asarifolia in DNBS-Induced Colitis in Rats. Int J Mol Sci 2018;19:E4016. [PMID: 30545135 DOI: 10.3390/ijms19124016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
82 Hall MJ, Morris AM, Sun W. Precision Medicine Versus Population Medicine in Colon Cancer: From Prospects of Prevention, Adjuvant Chemotherapy, and Surveillance. Am Soc Clin Oncol Educ Book 2018;38:220-30. [PMID: 30231337 DOI: 10.1200/EDBK_200961] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
83 Hoekman DR, Stibbe JA, Baert FJ, Caenepeel P, Vergauwe P, De Vos M, Hommes DW, Benninga MA, Vermeire SA, D'Haens GR; BIRD (Belgian Inflammatory Bowel Disease Research and Development) Group; North-Holland Gut Club. Long-term Outcome of Early Combined Immunosuppression Versus Conventional Management in Newly Diagnosed Crohn's Disease. J Crohns Colitis. 2018;12:517-524. [PMID: 29401297 DOI: 10.1093/ecco-jcc/jjy014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
84 Galanopoulos M, Tsoukali E, Gkeros F, Vraka M, Karampekos G, Matzaris GJ. Screening and surveillance methods for dysplasia in inflammatory bowel disease patients: Where do we stand? World J Gastrointest Endosc 2018; 10(10): 250-258 [PMID: 30364842 DOI: 10.4253/wjge.v10.i10.250] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
85 Eliakim R, Spada C, Lapidus A, Eyal I, Pecere S, Fernández-Urién I, Lahat A, Costamagna G, Schwartz A, Ron Y, Yanai H, Adler S. Evaluation of a new pan-enteric video capsule endoscopy system in patients with suspected or established inflammatory bowel disease - feasibility study. Endosc Int Open 2018;6:E1235-46. [PMID: 30302381 DOI: 10.1055/a-0677-170] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
86 Kaur M, Singapura P, Kalakota N, Cruz G, Shukla R, Ahsan S, Tansel A, Thrift AP, El-serag HB. Factors That Contribute to Indeterminate Results From the QuantiFERON-TB Gold In-Tube Test in Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 2018;16:1616-1621.e1. [DOI: 10.1016/j.cgh.2017.11.038] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
87 Sandborn WJ, Lee SD, Tarabar D, Louis E, Klopocka M, Klaus J, Reinisch W, Hébuterne X, Park DI, Schreiber S, Nayak S, Ahmad A, Banerjee A, Brown LS, Cataldi F, Gorelick KJ, Cheng JB, Hassan-Zahraee M, Clare R, D'Haens GR. Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study. Gut 2018;67:1824-35. [PMID: 28982740 DOI: 10.1136/gutjnl-2016-313457] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 14.3] [Reference Citation Analysis]
88 Sánchez A, Ramírez de la Piscina P, Duca I, Estrada S, Calderón R, Salvador M, Delgado E, García Campos F. Methotrexate Pneumonitis in Crohn's Disease: A Rare Case Report and Review of Literature. Arch Bronconeumol (Engl Ed) 2018;54:535-6. [PMID: 29503065 DOI: 10.1016/j.arbres.2018.01.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
89 Mogensen DV, Brynskov J, Ainsworth MA, Nersting J, Schmiegelow K, Steenholdt C. A Role for Thiopurine Metabolites in the Synergism Between Thiopurines and Infliximab in Inflammatory Bowel Disease. J Crohns Colitis 2018;12:298-305. [PMID: 29145599 DOI: 10.1093/ecco-jcc/jjx149] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
90 Shi LS, Liu PC, Tseng YF, Chen YL, Ye YL. Sweet Olive Extract Attenuates Dextran Sulfate Sodium-Induced Colitis in Mice. J Med Food 2018;21:1244-52. [PMID: 30153075 DOI: 10.1089/jmf.2018.4196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
91 Zhou H, Qian H. Preparation and characterization of pH-sensitive nanoparticles of budesonide for the treatment of ulcerative colitis. Drug Des Devel Ther 2018;12:2601-9. [PMID: 30174414 DOI: 10.2147/DDDT.S170676] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
92 Wilkins J, Ghosh P, Vivar J, Chakraborty B, Ghosh S. Exploring the associations between systemic inflammation, obesity and healthy days: a health related quality of life (HRQOL) analysis of NHANES 2005-2008. BMC Obes 2018;5:21. [PMID: 30123515 DOI: 10.1186/s40608-018-0196-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
93 López-sanromán A, Clofent J, Garcia-planella E, Menchén L, Nos P, Rodríguez-lago I, Domènech E. Reviewing the therapeutic role of budesonide in Crohn's disease. Gastroenterología y Hepatología (English Edition) 2018;41:458-71. [DOI: 10.1016/j.gastre.2018.07.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
94 Nelson SM, Nguyen TM, McDonald JW, MacDonald JK. Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2018;8:CD006097. [PMID: 30068022 DOI: 10.1002/14651858.CD006097.pub3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
95 Lee JH, Park YE, Seo N, Lee HJ, Park SJ, Kim TI, Kim WH, Lim JS, Cheon JH. Magnetic resonance enterography predicts the prognosis of Crohn's disease. Intest Res 2018;16:445-57. [PMID: 30090044 DOI: 10.5217/ir.2018.16.3.445] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
96 Xu Y, Yang L, An P, Zhou B, Liu G. Meta-Analysis: The Influence of Preoperative Infliximab Use on Postoperative Complications of Crohn’s Disease. Inflammatory Bowel Diseases 2019;25:261-9. [DOI: 10.1093/ibd/izy246] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
97 Basson AR, Lam M, Cominelli F. Complementary and Alternative Medicine Strategies for Therapeutic Gut Microbiota Modulation in Inflammatory Bowel Disease and their Next-Generation Approaches. Gastroenterol Clin North Am. 2017;46:689-729. [PMID: 29173517 DOI: 10.1016/j.gtc.2017.08.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
98 López-Sanromán A, Clofent J, Garcia-Planella E, Menchén L, Nos P, Rodríguez-Lago I, Domènech E. Reviewing the therapeutic role of budesonide in Crohn's disease. Gastroenterol Hepatol 2018;41:458-71. [PMID: 30007787 DOI: 10.1016/j.gastrohep.2018.05.013] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
99 Khatri G, Coleman J, Leyendecker JR. Magnetic Resonance Enterography for Inflammatory and Noninflammatory Conditions of the Small Bowel. Radiol Clin North Am. 2018;56:671-689. [PMID: 30119767 DOI: 10.1016/j.rcl.2018.04.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
100 Ma C, Ascoytia C, Mccarrier KP, Martin M, Feagan BG, Jairath V. Physicians’ Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn’s Disease. Dig Dis Sci 2018;63:2555-63. [DOI: 10.1007/s10620-018-5181-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
101 Iwamoto F, Matsuoka K, Motobayashi M, Takenaka K, Kuno T, Tanaka K, Tsukui Y, Kobayashi S, Yoshida T, Fujii T, Saito E, Yamaguchi T, Nagahori M, Sato T, Ohtsuka K, Enomoto N, Watanabe M. Prediction of disease activity of Crohn's disease through fecal calprotectin evaluated by balloon-assisted endoscopy. J Gastroenterol Hepatol 2018;33:1984-9. [PMID: 29889986 DOI: 10.1111/jgh.14310] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
102 Junga Z, Theeler B, Singla M. Infliximab-Induced Aseptic Meningitis in a Patient with Crohn's Disease. ACG Case Rep J 2018;5:e48. [PMID: 29951563 DOI: 10.14309/crj.2018.48] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
103 Strohl M, Gonczi L, Kurt Z, Bessissow T, L Lakatos P. Quality of care in inflammatory bowel diseases: What is the best way to better outcomes? World J Gastroenterol 2018; 24(22): 2363-2372 [PMID: 29904243 DOI: 10.3748/wjg.v24.i22.2363] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
104 Chabot K, Lavoie ME, Bastard JP, Rabasa-Lhoret R. Intravenous catheters induce a local inflammatory response. Cytokine 2018;111:470-4. [PMID: 29903592 DOI: 10.1016/j.cyto.2018.05.034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
105 Zhu NY, Zhao XS, Miao F. Magnetic resonance imaging and Crohn’s disease endoscopic index of severity: Correlations and concordance. World J Gastroenterol 2018; 24(21): 2279-2290 [PMID: 29881237 DOI: 10.3748/wjg.v24.i21.2279] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
106 Sundin J, Öhman L, Simrén M. Understanding the Gut Microbiota in Inflammatory and Functional Gastrointestinal Diseases. Psychosom Med 2017;79:857-67. [PMID: 28422780 DOI: 10.1097/PSY.0000000000000470] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 6.5] [Reference Citation Analysis]
107 Ma C, Dutton SJ, Cipriano LE, Singh S, Parker CE, Nguyen TM, Guizzetti L, Gregor JC, Chande N, Hindryckx P, Feagan BG, Jairath V. Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease. Aliment Pharmacol Ther 2018;48:114-26. [PMID: 29851091 DOI: 10.1111/apt.14821] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
108 Mudireddy P, Scott F, Feathers A, Lichtenstein GR. Inflammatory Bowel Disease: Predictors and Causes of Early and Late Hospital Readmissions. Inflamm Bowel Dis 2017;23:1832-9. [PMID: 28858068 DOI: 10.1097/MIB.0000000000001242] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
109 Sandborn WJ, Rutgeerts P, Colombel JF, Ghosh S, Petryka R, Sands BE, Mitra P, Luo A. Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study. J Crohns Colitis 2017;11:811-9. [PMID: 28333187 DOI: 10.1093/ecco-jcc/jjx005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
110 Zhang P, Minardi LM, Kuenstner JT, Zekan SM, Kruzelock R. Anti-microbial Antibodies, Host Immunity, and Autoimmune Disease. Front Med (Lausanne) 2018;5:153. [PMID: 29876352 DOI: 10.3389/fmed.2018.00153] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
111 Dorreen A, Heisler C, Jones J. Treatment of Inflammatory Bowel Disease in the Older Patient. Inflammatory Bowel Diseases 2018;24:1155-66. [DOI: 10.1093/ibd/izy023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
112 Singla MB, Eickhoff C, Betteridge J. Extraintestinal Manifestations Are Common in Obese Patients with Crohn's Disease. Inflamm Bowel Dis 2017;23:1637-42. [PMID: 28691941 DOI: 10.1097/MIB.0000000000001187] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
113 Bessissow T, Reinglas J, Aruljothy A, Lakatos PL, Van Assche G. Endoscopic management of Crohn’s strictures. World J Gastroenterol 2018; 24(17): 1859-1867 [PMID: 29740201 DOI: 10.3748/wjg.v24.i17.1859] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
114 Wang X, Shen B. Management of Crohn’s Disease and Complications in Patients With Ostomies. Inflammatory Bowel Diseases 2018;24:1167-84. [DOI: 10.1093/ibd/izy025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
115 Hansen T, Duerksen DR. Enteral Nutrition in the Management of Pediatric and Adult Crohn's Disease. Nutrients 2018;10:E537. [PMID: 29701656 DOI: 10.3390/nu10050537] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
116 Park Y, Cheon JH, Park YL, Ye BD, Kim YS, Han DS, Kim JS, Hong SN, Kim YH, Jeon SR, Kim WH; IBD Study Group of the Korean Association for the Study of Intestinal Diseases (KASID). Development of a Novel Predictive Model for the Clinical Course of Crohn's Disease: Results from the CONNECT Study. Inflamm Bowel Dis. 2017;23:1071-1079. [PMID: 28410345 DOI: 10.1097/mib.0000000000001106] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
117 Buhl S, Steenholdt C, Rasmussen M, Borghede MK, Brynskov J, Thomsen OØ, Ainsworth MA. Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:1210-7. [PMID: 28445244 DOI: 10.1097/MIB.0000000000001117] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
118 Vaughn DA, van Deen WK, Kerr WT, Meyer TR, Bertozzi AL, Hommes DW, Cohen MS. Using insurance claims to predict and improve hospitalizations and biologics use in members with inflammatory bowel diseases. J Biomed Inform 2018;81:93-101. [PMID: 29625187 DOI: 10.1016/j.jbi.2018.03.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
119 Hanada Y, Khanna S, Loftus EV, Raffals LE, Pardi DS. Non– Clostridium difficile Bacterial Infections Are Rare in Patients With Flares of Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 2018;16:528-33. [DOI: 10.1016/j.cgh.2017.10.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
120 Wilson A, Jansen LE, Rose RV, Gregor JC, Ponich T, Chande N, Khanna R, Yan B, Jairath V, Khanna N, Sey M, Beaton M, McIntosh K, Teft WA, Kim RB. Letter: predicting azathioprine-associated pancreatitis in IBD-phenotype or genotype? Authors' reply. Aliment Pharmacol Ther 2018;47:1044-5. [PMID: 29512906 DOI: 10.1111/apt.14562] [Reference Citation Analysis]
121 Tang MT, Keir ME, Erickson R, Stefanich EG, Fuh FK, Ramirez-Montagut T, McBride JM, Danilenko DM. Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease. Aliment Pharmacol Ther 2018;47:1440-52. [PMID: 29601644 DOI: 10.1111/apt.14631] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
122 Tsui JJ, Huynh HQ. Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn's disease? Ann Gastroenterol 2018;31:413-24. [PMID: 29991886 DOI: 10.20524/aog.2018.0253] [Cited by in Crossref: 3] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
123 Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol. 2018;113:481-517. [PMID: 29610508 DOI: 10.1038/ajg.2018.27] [Cited by in Crossref: 390] [Cited by in F6Publishing: 451] [Article Influence: 97.5] [Reference Citation Analysis]
124 Khan N, Vallarino C, Lissoos T, Darr U, Luo M. Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients. Drugs Aging 2017;34:859-68. [PMID: 29170864 DOI: 10.1007/s40266-017-0498-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
125 Ananthakrishnan AN, Donaldson T, Lasch K, Yajnik V. Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities. Inflamm Bowel Dis. 2017;23:882-893. [PMID: 28375885 DOI: 10.1097/mib.0000000000001099] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 10.8] [Reference Citation Analysis]
126 Talabur Horje CS, Meijer J, Rovers L, van Lochem EG, Groenen MJ, Wahab PJ. Prevalence of Upper Gastrointestinal Lesions at Primary Diagnosis in Adults with Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:E33-4. [PMID: 27542141 DOI: 10.1097/MIB.0000000000000888] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
127 Sarid O, Slonim-nevo V, Schwartz D, Friger M, Sergienko R, Pereg A, Vardi H, Chernin E, Singer T, Greenberg D, Odes S; on behalf of the Israel IBD Research Nucleus (IIRN). Differing Relationship of Psycho-Social Variables with Active Ulcerative Colitis or Crohn’s Disease. Int J Behav Med 2018;25:341-50. [DOI: 10.1007/s12529-018-9712-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
128 Li Y, Ren JA, Wang GF, Gu GS, Wu XW, Liu S, Ren HJ, Hong ZW, Li JS. Impaired Coagulation Status in the Crohn's Disease Patients Complicated with Intestinal Fistula. Chin Med J (Engl) 2018;131:567-73. [PMID: 29483391 DOI: 10.4103/0366-6999.226072] [Reference Citation Analysis]
129 Walker C, Allamneni C, Orr J, Yun H, Fitzmorris P, Xie F, Malik TA. Socioeconomic Status and Race are both Independently associated with Increased Hospitalization Rate among Crohn's Disease Patients. Sci Rep 2018;8:4028. [PMID: 29507339 DOI: 10.1038/s41598-018-22429-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
130 Lan N, Stocchi L, Ashburn JH, Hull TL, Steele SR, Delaney CP, Shen B. Outcomes of Endoscopic Balloon Dilation vs Surgical Resection for Primary Ileocolic Strictures in Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2018;16:1260-7. [PMID: 29505909 DOI: 10.1016/j.cgh.2018.02.035] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
131 Kamat N, Rajan Mallayasamy S, Sharma PSVN, Kamath A, Pai CG. Video assisted patient education improves compliance with follow up and depression scores in Inflammatory Bowel Diseases. Postgrad Med 2018;130:355-60. [PMID: 29460659 DOI: 10.1080/00325481.2018.1442978] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
132 Shah ED, Farida JP, Siegel CA, Chong K, Melmed GY. Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2017;23:570-577. [PMID: 28230558 DOI: 10.1097/mib.0000000000001049] [Cited by in Crossref: 67] [Cited by in F6Publishing: 55] [Article Influence: 16.8] [Reference Citation Analysis]
133 Sands BE, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naive to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. Inflammatory bowel diseases. 2017;23:97-106. [PMID: 27930408 DOI: 10.1097/mib.0000000000000979] [Cited by in Crossref: 107] [Cited by in F6Publishing: 97] [Article Influence: 26.8] [Reference Citation Analysis]
134 Maya Y, Narasaki W, Maeda Y, Ota M. A Refractory Cutaneous Abscess. Am J Med 2018;131:e259-60. [PMID: 29453940 DOI: 10.1016/j.amjmed.2018.01.028] [Reference Citation Analysis]
135 Geisz M, Ha C, Kappelman MD, Martin CF, Chen W, Anton K, Sandler RS, Long MD. Medication Utilization and the Impact of Continued Corticosteroid Use on Patient-reported Outcomes in Older Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:1435-41. [PMID: 26978725 DOI: 10.1097/MIB.0000000000000747] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
136 Tan CX, Brand HS, de Boer NK, Forouzanfar T. Gastrointestinal diseases and their oro-dental manifestations: Part 1: Crohn's disease. Br Dent J 2016;221:794-9. [PMID: 27982000 DOI: 10.1038/sj.bdj.2016.954] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
137 Ashton JJ, Gavin J, Beattie RM. Exclusive enteral nutrition in Crohn's disease: Evidence and practicalities. Clin Nutr. 2019;38:80-89. [PMID: 29398336 DOI: 10.1016/j.clnu.2018.01.020] [Cited by in Crossref: 34] [Cited by in F6Publishing: 47] [Article Influence: 8.5] [Reference Citation Analysis]
138 Sanchez IM, Jiang W, Yang EJ, Singh RK, Beck K, Liu C, Afifi L, Liao W. Enteropathy in Psoriasis: A Systematic Review of Gastrointestinal Disease Epidemiology and Subclinical Inflammatory and Functional Gut Alterations. Curr Derm Rep 2018;7:59-74. [DOI: 10.1007/s13671-018-0213-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
139 Freeman K, Connock M, Auguste P, Taylor-Phillips S, Mistry H, Shyangdan D, Court R, Arasaradnam R, Sutcliffe P, Clarke A. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling. Health Technol Assess 2016;20:1-288. [PMID: 27845027 DOI: 10.3310/hta20830] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
140 Hiraoka S, Takashima S, Kondo Y, Inokuchi T, Sugihara Y, Takahara M, Kawano S, Harada K, Kato J, Okada H. Efficacy of restarting anti-tumor necrosis factor α agents after surgery in patients with Crohn's disease. Intest Res 2018;16:75-82. [PMID: 29422801 DOI: 10.5217/ir.2018.16.1.75] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
141 Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305-353. [PMID: 29429045 DOI: 10.1007/s00535-018-1439-1] [Cited by in Crossref: 252] [Cited by in F6Publishing: 214] [Article Influence: 63.0] [Reference Citation Analysis]
142 Berkowitz JC, Stein-Fishbein J, Khan S, Furie R, Sultan KS. Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting. World J Gastrointest Pharmacol Ther 2018; 9(1): 8-13 [PMID: 29430323 DOI: 10.4292/wjgpt.v9.i1.8] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
143 Horjus Talabur Horje CS, Meijer J, Rovers L, van Lochem EG, Groenen MJ, Wahab PJ. Prevalence of Upper Gastrointestinal Lesions at Primary Diagnosis in Adults with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22:1896-1901. [PMID: 27057685 DOI: 10.1097/mib.0000000000000786] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 9.8] [Reference Citation Analysis]
144 Siegel CA, Whitman CB, Spiegel BMR, Feagan B, Sands B, Loftus EV Jr, Panaccione R, D'Haens G, Bernstein CN, Gearry R, Ng SC, Mantzaris GJ, Sartor B, Silverberg MS, Riddell R, Koutroubakis IE, O'Morain C, Lakatos PL, McGovern DPB, Halfvarson J, Reinisch W, Rogler G, Kruis W, Tysk C, Schreiber S, Danese S, Sandborn W, Griffiths A, Moum B, Gasche C, Pallone F, Travis S, Panes J, Colombel JF, Hanauer S, Peyrin-Biroulet L. Development of an index to define overall disease severity in IBD. Gut 2018;67:244-54. [PMID: 27780886 DOI: 10.1136/gutjnl-2016-312648] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 17.8] [Reference Citation Analysis]
145 Lee MJ, Parker CE, Taylor SR, Guizzetti L, Feagan BG, Lobo AJ, Jairath V. Efficacy of Medical Therapies for Fistulizing Crohn's Disease: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018;16:1879-1892. [PMID: 29374617 DOI: 10.1016/j.cgh.2018.01.030] [Cited by in Crossref: 66] [Cited by in F6Publishing: 52] [Article Influence: 16.5] [Reference Citation Analysis]
146 Mcconachie SM, Wilhelm SM, Bhargava A, Kale-pradhan PB. Biologic-Induced Infections in Inflammatory Bowel Disease: The TNF-α Antagonists. Ann Pharmacother 2018;52:571-9. [DOI: 10.1177/1060028018754896] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
147 Buisson A, Bringer MA, Barnich N, Vazeille E. Macrophages Versus Escherichia coli: A Decisive Fight in Crohn's Disease. Inflamm Bowel Dis 2016;22:2943-55. [PMID: 27824652 DOI: 10.1097/MIB.0000000000000946] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
148 Vermeire S, Gils A, Accossato P, Lula S, Marren A. Immunogenicity of biologics in inflammatory bowel disease. Therap Adv Gastroenterol. 2018;11:1756283X17750355. [PMID: 29383030 DOI: 10.1177/1756283x17750355] [Cited by in Crossref: 90] [Cited by in F6Publishing: 104] [Article Influence: 22.5] [Reference Citation Analysis]
149 Feuerstein JD, Curran T, Alosilla M, Cataldo T, Falchuk KR, Poylin V. Mortality Is Rare Following Elective and Non-elective Surgery for Ulcerative Colitis, but Mild Postoperative Complications Are Common.Dig Dis Sci. 2018;63:713-722. [PMID: 29353444 DOI: 10.1007/s10620-018-4922-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
150 Megna B, Saha S, Wald A, Agni R, Matkowskyj KA, Caldera F. Symptomatic Microscopic Colitis Atop Quiescent Inflammatory Bowel Disease: A Case Series. ACG Case Rep J 2017;4:e124. [PMID: 29299484 DOI: 10.14309/crj.2017.124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
151 Colizzo FP, Friedman LS. Editorial: avoiding corticosteroids in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2018;47:143-4. [PMID: 29226421 DOI: 10.1111/apt.14399] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
152 Malikowski T, Khanna S, Pardi DS. Fecal microbiota transplantation for gastrointestinal disorders. Curr Opin Gastroenterol 2017;33:8-13. [PMID: 28134687 DOI: 10.1097/MOG.0000000000000326] [Cited by in Crossref: 14] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
153 Ishihara S, Tada Y, Kawashima K, Kataoka M, Sonoyama H, Yamashita N, Oka A, Kusunoki R, Fukuba N, Mishima Y, Oshima N, Moriyama I, Yuki T, Kinoshita Y. Serum amyloid A level correlated with endoscopic findings in patients with Crohn's disease-Possible biomarker for evaluating mucosal healing. Dig Liver Dis 2018;50:553-8. [PMID: 29311027 DOI: 10.1016/j.dld.2017.12.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
154 Sarid O, Slonim-Nevo V, Sergienko R, Pereg A, Chernin E, Singer T, Greenberg D, Schwartz D, Vardi H, Friger M, Odes S. Daily hassles score associates with the somatic and psychological health of patients with Crohn's disease. J Clin Psychol 2018;74:969-88. [PMID: 29244192 DOI: 10.1002/jclp.22561] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
155 Kobayashi T, Hishida A, Tanaka H, Nuki Y, Bamba S, Yamada A, Fujii T, Shinzaki S, Yokoyama Y, Yoshida A, Ozeki K, Ashizuka S, Kamata N, Nanjo S, Kakimoto K, Nakamura M, Matsui A, Yamauchi R, Takahashi S, Tomizawa T, Yoshino T, Hibi T. Real-world Experience of Anti–tumor Necrosis Factor Therapy for Internal Fistulas in Crohnʼs Disease: A Retrospective Multicenter Cohort Study. Inflammatory Bowel Diseases 2017;23:2245-51. [DOI: 10.1097/mib.0000000000001276] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
156 Zhang AF, Miao YL. Strategies for remission induction of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2017; 25(33): 2938-2944 [DOI: 10.11569/wcjd.v25.i33.2938] [Reference Citation Analysis]
157 Yokoyama T, Ohta A, Motoya S, Takazoe M, Yajima T, Date M, Nii M, Nagy P, Suzuki Y, Hibi T. Efficacy and Safety of Oral Budesonide in Patients with Active Crohn's Disease in Japan: A Multicenter, Double-Blind, Randomized, Parallel-Group Phase 3 Study. Inflamm Intest Dis. 2018;2:154-162. [PMID: 29922676 DOI: 10.1159/000484047] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
158 Atsawarungruangkit A, Dominguez F, Borda G, Mavrogiorgos N. Listeria Monocytogenes Brain Abscess in Crohn's Disease Treated with Adalimumab. Case Rep Gastroenterol 2017;11:667-71. [PMID: 29282389 DOI: 10.1159/000481165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
159 Sairenji T, Collins KL, Evans DV. An Update on Inflammatory Bowel Disease. Prim Care. 2017;44:673-692. [PMID: 29132528 DOI: 10.1016/j.pop.2017.07.010] [Cited by in Crossref: 127] [Cited by in F6Publishing: 170] [Article Influence: 25.4] [Reference Citation Analysis]
160 Kim ES. Role of Advanced Endoscopic Imaging Techniques in the Management of Inflammatory Bowel Disease. Clin Endosc 2017;50:424-8. [PMID: 29017290 DOI: 10.5946/ce.2017.143] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
161 Santos JCD, Malaguti C, Lucca FA, Cabalzar AL, Ribeiro TCDR, Gaburri PD, Chebli LA, Chebli JMF. Impact of biological therapy on body composition of patients with Chron's disease.Rev Assoc Med Bras (1992). 2017;63:407-413. [PMID: 28724037 DOI: 10.1590/1806-9282.63.05.407] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
162 Dudley-Brown S. Optimizing Inflammatory Bowel Disease Management: An Overview for the Gastroenterology Nurse. Gastroenterol Nurs 2017;40 Suppl 1S:S1-S14. [PMID: 27922458 DOI: 10.1097/SGA.0000000000000277] [Reference Citation Analysis]
163 Baena-Díez JM, Garcia-Gil M, Comas-Cufí M, Ramos R, Prieto-Alhambra D, Salvador-González B, Elosua R, Dégano IR, Peñafiel J, Grau M. Association between chronic immune-mediated inflammatory diseases and cardiovascular risk. Heart 2018;104:119-26. [PMID: 28847852 DOI: 10.1136/heartjnl-2017-311279] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 6.4] [Reference Citation Analysis]
164 Qiao YQ, Cai CW, Ran ZH. Therapeutic modulation of gut microbiota in inflammatory bowel disease: More questions to be answered. J Dig Dis. 2016;17:800-810. [PMID: 27743467 DOI: 10.1111/1751-2980.12422] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
165 Gajendran M, Loganathan P, Catinella AP, Hashash JG. A comprehensive review and update on Crohn's disease. Dis Mon. 2018;64:20-57. [PMID: 28826742 DOI: 10.1016/j.disamonth.2017.07.001] [Cited by in Crossref: 108] [Cited by in F6Publishing: 138] [Article Influence: 21.6] [Reference Citation Analysis]
166 Kamat N, Ganesh Pai C, Surulivel Rajan M, Kamath A. Cost of Illness in Inflammatory Bowel Disease. Dig Dis Sci. 2017;62:2318-2326. [PMID: 28766243 DOI: 10.1007/s10620-017-4690-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
167 Statovci D, Aguilera M, MacSharry J, Melgar S. The Impact of Western Diet and Nutrients on the Microbiota and Immune Response at Mucosal Interfaces. Front Immunol. 2017;8:838. [PMID: 28804483 DOI: 10.3389/fimmu.2017.00838] [Cited by in Crossref: 163] [Cited by in F6Publishing: 182] [Article Influence: 32.6] [Reference Citation Analysis]
168 He Z, Li P, Zhu J, Cui B, Xu L, Xiang J, Zhang T, Long C, Huang G, Ji G, Nie Y, Wu K, Fan D, Zhang F. Multiple fresh fecal microbiota transplants induces and maintains clinical remission in Crohn's disease complicated with inflammatory mass. Sci Rep. 2017;7:4753. [PMID: 28684845 DOI: 10.1038/s41598-017-04984-z] [Cited by in Crossref: 42] [Cited by in F6Publishing: 50] [Article Influence: 8.4] [Reference Citation Analysis]
169 Sartini A, Gitto S, Villa E. Does Metabolic Syndrome and Not the Inflammatory Load Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients? Dig Dis Sci 2017;62:2604-6. [DOI: 10.1007/s10620-017-4665-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
170 Martinez B, Dailey F, Almario CV, Keller MS, Desai M, Dupuy T, Mosadeghi S, Whitman C, Lasch K, Ursos L, Spiegel BM. Patient Understanding of the Risks and Benefits of Biologic Therapies in Inflammatory Bowel Disease: Insights from a Large-scale Analysis of Social Media Platforms. Inflammatory Bowel Diseases 2017;23:1057-64. [DOI: 10.1097/mib.0000000000001110] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
171 Derwa Y, Gracie DJ, Hamlin PJ, Ford AC. Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46:389-400. [PMID: 28653751 DOI: 10.1111/apt.14203] [Cited by in Crossref: 211] [Cited by in F6Publishing: 184] [Article Influence: 42.2] [Reference Citation Analysis]
172 Schüle S, Rossel JB, Frey D, Biedermann L, Scharl M, Zeitz J, Freitas-Queiroz N, Kuntzen T, Greuter T, Vavricka SR, Rogler G, Misselwitz B; Swiss IBD cohort study. Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study. Medicine (Baltimore) 2017;96:e6788. [PMID: 28562531 DOI: 10.1097/MD.0000000000006788] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
173 Wei SC, Chang TA, Chao TH, Chen JS, Chou JW, Chou YH, Chuang CH, Hsu WH, Huang TY, Hsu TC, Lin CC, Lin HH, Lin JK, Lin WC, Ni YH, Shieh MJ, Shih IL, Shun CT, Tsang YM, Wang CY, Wang HY, Weng MT, Wu DC, Wu WC, Yen HH, Wong JM. Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. Intest Res 2017;15:285-310. [PMID: 28670226 DOI: 10.5217/ir.2017.15.3.285] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
174 Feuerstein JD, Cheifetz AS. Crohn Disease: Epidemiology, Diagnosis, and Management. Mayo Clin Proc. 2017;92:1088-1103. [PMID: 28601423 DOI: 10.1016/j.mayocp.2017.04.010] [Cited by in Crossref: 111] [Cited by in F6Publishing: 136] [Article Influence: 22.2] [Reference Citation Analysis]
175 Huang LC, Merchea A. Dysplasia and Cancer in Inflammatory Bowel Disease. Surgical Clinics of North America 2017;97:627-39. [DOI: 10.1016/j.suc.2017.01.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
176 Feitosa MR, Féres Filho O, Tamaki CM, Perazzoli C, Bernardes MV, Parra RS, Rocha JJ, Féres O. Adjunctive Hyperbaric Oxygen Therapy promotes successful healing in patients with refractory Crohn's disease. Acta Cir Bras 2016;31 Suppl 1:19-23. [PMID: 27142900 DOI: 10.1590/S0102-86502016001300005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
177 Gawron I, Chmura L, Adamek D, Skotniczny K, Pityński K, Ludwin A. Laparoscopic Intervention in Acute Crohn's Disease Involving an Ovary. J Minim Invasive Gynecol 2017;24:1040-5. [PMID: 28559086 DOI: 10.1016/j.jmig.2017.04.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
178 Park JJ, Yang SK, Ye BD, Kim JW, Park DI, Yoon H, Im JP, Lee KM, Yoon SN, Lee H; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. [Second Korean Guidelines for the Management of Crohn's Disease]. Korean J Gastroenterol 2017;69:29-54. [PMID: 28135790 DOI: 10.4166/kjg.2017.69.1.29] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
179 Rao VL, Micic D, Kim KE. Primary Care Evaluation and Management of Gastroenterologic Issues in Women. Obstet Gynecol Clin North Am 2016;43:347-66. [PMID: 27212096 DOI: 10.1016/j.ogc.2016.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
180 Sultan KS, Berkowitz JC, Khan S. Combination therapy for inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2017; 8(2): 103-113 [PMID: 28533919 DOI: 10.4292/wjgpt.v8.i2.103] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
181 Gordon M. 5-Aminosalicylates to maintain remission in Crohn’s disease: Interpreting conflicting systematic review evidence. World J Gastrointest Pharmacol Ther 2017; 8(2): 99-102 [PMID: 28533918 DOI: 10.4292/wjgpt.v8.i2.99] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
182 Bounthavong M, Li M, Watanabe JH. An evaluation of health care expenditures in Crohn's disease using the United States Medical Expenditure Panel Survey from 2003 to 2013. Research in Social and Administrative Pharmacy 2017;13:530-8. [DOI: 10.1016/j.sapharm.2016.05.042] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
183 Coward S, Kuenzig ME, Hazlewood G, Clement F, McBrien K, Holmes R, Panaccione R, Ghosh S, Seow CH, Rezaie A, Kaplan GG. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis: Republished. Inflamm Bowel Dis. 2017;23:E26-E37. [PMID: 30052985 DOI: 10.1097/mib.0000000000001158] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
184 Bonovas S, Peyrin-Biroulet L, Danese S. Is Mesalamine Effective for the Induction of Remission in Crohn's Disease? Inflamm Bowel Dis 2017;23:E22-3. [PMID: 28426460 DOI: 10.1097/MIB.0000000000001124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
185 Patel H, Lissoos T, Rubin DT. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States. PLoS One 2017;12:e0175099. [PMID: 28426675 DOI: 10.1371/journal.pone.0175099] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
186 Venkata KVR, Arora SS, Xie FL, Malik TA. Impact of vitamin D on the hospitalization rate of Crohn's disease patients seen at a tertiary care center. World J Gastroenterol 2017; 23(14): 2539-2544 [PMID: 28465638 DOI: 10.3748/wjg.v23.i14.2539] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
187 Malarcher CA, Wheaton AG, Liu Y, Greenlund SF, Greenlund SJ, Lu H, Croft JB. Hospitalizations for Crohn's Disease - United States, 2003-2013. MMWR Morb Mortal Wkly Rep 2017;66:377-81. [PMID: 28406887 DOI: 10.15585/mmwr.mm6614a1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
188 Lightner AL, Shen B. Perioperative use of immunosuppressive medications in patients with Crohn's disease in the new "biological era". Gastroenterol Rep (Oxf) 2017;5:165-77. [PMID: 28852521 DOI: 10.1093/gastro/gow046] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
189 Lee KE, Jung S, Yoon H, Park SH, Moon CM, Kim ES, Kim S, Yang S. Factors associated with pregnancy-related knowledge in women of reproductive age with inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2017;52:833-9. [DOI: 10.1080/00365521.2017.1310288] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
190 Deepak P, Park SH, Ehman EC, Hansel SL, Fidler JL, Bruining DH, Fletcher JG. Crohn's disease diagnosis, treatment approach, and management paradigm: what the radiologist needs to know. Abdom Radiol (NY) 2017;42:1068-86. [PMID: 28210767 DOI: 10.1007/s00261-017-1068-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
191 Oliveira IS, Kilcoyne A, Price MC, Harisinghani M. MRI features of perianal fistulas: is there a difference between Crohn's and non-Crohn's patients? Abdom Radiol (NY) 2017;42:1162-8. [PMID: 27885389 DOI: 10.1007/s00261-016-0989-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
192 Bolge SC, Eldridge HM, Lofland JH, Ravin C, Hart PJ, Ingham MP. Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn's disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis. Patient Prefer Adherence 2017;11:661-9. [PMID: 28405158 DOI: 10.2147/PPA.S121032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
193 Pereira SR, Pereira R, Figueiredo I, Freitas V, Dinis TC, Almeida LM. Comparison of anti-inflammatory activities of an anthocyanin-rich fraction from Portuguese blueberries (Vaccinium corymbosum L.) and 5-aminosalicylic acid in a TNBS-induced colitis rat model. PLoS One. 2017;12:e0174116. [PMID: 28329021 DOI: 10.1371/journal.pone.0174116] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 6.8] [Reference Citation Analysis]
194 Yamamoto-Furusho JK, Bosques-Padilla F, Daffra P, De Paula JA, Etchevers J, Galiano MT, Ibañez P, Juliao F, Kotze PG, Marroquín de la Garza JM, Monreal Robles R, Rocha JL, Steinwurz F, Vázquez-Frías R, Veitia G, Zaltman C. Special situations in inflammatory bowel disease: First Latin American consensus of the Pan American Crohn's and Colitis Organisation (PANCCO) (Second part). Rev Gastroenterol Mex 2017;82:134-55. [PMID: 28318706 DOI: 10.1016/j.rgmx.2016.07.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
195 Gallego JC, Echarri A. Is there a role of magnetic resonance imaging in deciding to stop anti-tumor necrosis factor treatment in ileal Crohn's disease? Clin Imaging 2017;43:175-9. [PMID: 28334618 DOI: 10.1016/j.clinimag.2017.03.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
196 Azer SA, AlOlayan TI, AlGhamdi MA, AlSanea MA. Inflammatory bowel disease: An evaluation of health information on the internet. World J Gastroenterol 2017; 23(9): 1676-1696 [PMID: 28321169 DOI: 10.3748/wjg.v23.i9.1676] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
197 Carr RM, Patel A, Bownik H, Oranu A, Kerner C, Praestgaard A, Forde KA, Reddy KR, Lichtenstein GR. Intestinal Inflammation Does Not Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients. Dig Dis Sci. 2017;62:1354-1361. [PMID: 28265826 DOI: 10.1007/s10620-017-4495-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
198 Coward S, Kuenzig ME, Hazlewood G, Clement F, Mcbrien K, Holmes R, Panaccione R, Ghosh S, Seow CH, Rezaie A, Kaplan GG. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohnʼs Disease: A Bayesian Network Meta-analysis. Inflammatory Bowel Diseases 2017;23:461-72. [DOI: 10.1097/mib.0000000000001023] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
199 Sarid O, Slonim-Nevo V, Pereg A, Friger M, Sergienko R, Schwartz D, Greenberg D, Shahar I, Chernin E, Vardi H, Eidelman L, Segal A, Ben-Yakov G, Gaspar N, Munteanu D, Rozental A, Mushkalo A, Dizengof V, Abu-Freha N, Fich A, Odes S; Israeli IBD Research Nucleus (IIRN). Coping strategies, satisfaction with life, and quality of life in Crohn's disease: A gender perspective using structural equation modeling analysis. PLoS One 2017;12:e0172779. [PMID: 28245260 DOI: 10.1371/journal.pone.0172779] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
200 Choi CH, Song ID, Kim YH, Koo JS, Kim YS, Kim JS, Kim N, Kim ES, Kim JH, Kim JW, Kim TO, Kim HS, Kim HJ, Park YS, Park DI, Park SJ, Song HJ, Shin SJ, Yang SK, Ye BD, Lee KM, Lee BI, Lee SY, Lee CK, Im JP, Jang BI, Jeon TJ, Cho YK, Chang SK, Jeon SR, Jung SA, Jeen YT, Cha JM, Han DS, Kim WH; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study. Yonsei Med J. 2016;57:1376-1385. [PMID: 27593865 DOI: 10.3349/ymj.2016.57.6.1376] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
201 Singh S, Chowdhry M, Umar S, Bilal M, Clarke K. Variations in the medical treatment of inflammatory bowel disease among gastroenterologists. Gastroenterol Rep (Oxf) 2018;6:61-4. [PMID: 29479445 DOI: 10.1093/gastro/gox005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
202 Afzali A, Ogden K, Friedman ML, Chao J, Wang A. Costs of providing infusion therapy for patients with inflammatory bowel disease in a hospital-based infusion center setting. Journal of Medical Economics 2017;20:409-22. [DOI: 10.1080/13696998.2017.1285779] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
203 Park JJ, Yang SK, Ye BD, Kim JW, Park DI, Yoon H, Im JP, Lee KM, Yoon SN, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of Crohn's disease. Intest Res 2017;15:38-67. [PMID: 28239314 DOI: 10.5217/ir.2017.15.1.38] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
204 Mcconachie S, Wilhelm SM, Kale-pradhan PB. Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence. Expert Review of Clinical Pharmacology 2017;10:391-400. [DOI: 10.1080/17512433.2017.1283983] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
205 Svolos V, Gerasimidis K, Buchanan E, Curtis L, Garrick V, Hay J, Laird S, Munro J, Gaya DR, Russell RK, Hansen R. Dietary treatment of Crohn's disease: perceptions of families with children treated by exclusive enteral nutrition, a questionnaire survey. BMC Gastroenterol 2017;17:14. [PMID: 28103809 DOI: 10.1186/s12876-016-0564-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
206 Calabrese E, Maaser C, Zorzi F, Kannengiesser K, Hanauer SB, Bruining DH, Iacucci M, Maconi G, Novak KL, Panaccione R, Strobel D, Wilson SR, Watanabe M, Pallone F, Ghosh S. Bowel Ultrasonography in the Management of Crohn's Disease. Inflamm Bowel Dis. 2016;22:1168-1183. [PMID: 26958988 DOI: 10.1097/mib.0000000000000706] [Cited by in Crossref: 91] [Cited by in F6Publishing: 74] [Article Influence: 18.2] [Reference Citation Analysis]
207 Lee CK. [Ideal vaccination strategy in inflammatory bowel disease]. Korean J Gastroenterol 2015;65:159-64. [PMID: 25797379 DOI: 10.4166/kjg.2015.65.3.159] [Reference Citation Analysis]
208 Huh J, Kim KJ, Park SH, Park SH, Yang SK, Ye BD, Park SH, Han K, Kim AY. Diffusion-Weighted MR Enterography to Monitor Bowel Inflammation after Medical Therapy in Crohn's Disease: A Prospective Longitudinal Study. Korean J Radiol. 2017;18:162-172. [PMID: 28096726 DOI: 10.3348/kjr.2017.18.1.162] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
209 Enns RA, Hookey L, Armstrong D, Bernstein CN, Heitman SJ, Teshima C, Leontiadis GI, Tse F, Sadowski D. Clinical Practice Guidelines for the Use of Video Capsule Endoscopy. Gastroenterology. 2017;152:497-514. [PMID: 28063287 DOI: 10.1053/j.gastro.2016.12.032] [Cited by in Crossref: 168] [Cited by in F6Publishing: 181] [Article Influence: 33.6] [Reference Citation Analysis]
210 Pence IJ, Beaulieu DB, Horst SN, Bi X, Herline AJ, Schwartz DA, Mahadevan-Jansen A. Clinical characterization of in vivo inflammatory bowel disease with Raman spectroscopy. Biomed Opt Express 2017;8:524-35. [PMID: 28270965 DOI: 10.1364/BOE.8.000524] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
211 Mocci G, Migaleddu V, Cabras F, Sirigu D, Scanu D, Virgilio G, Marzo M. SICUS and CEUS imaging in Crohn's disease: an update. J Ultrasound 2017;20:1-9. [PMID: 28298939 DOI: 10.1007/s40477-016-0230-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
212 Bilal M, Singh S, Lee H, Khosa K, Khehra R, Clarke K. Bridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-IBD gastroenterologists. Ann Gastroenterol 2017;30:192-6. [PMID: 28243040 DOI: 10.20524/aog.2016.0114] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
213 Walker CH, Arora SS, Colantonio LD, Kakati DD, Fitzmorris PS, Chu DI, Malik TA. Rates of hospitalization among African American and Caucasian American patients with Crohn's disease seen at a tertiary care center. Gastroenterol Rep (Oxf) 2017;5:288-92. [PMID: 27940604 DOI: 10.1093/gastro/gow036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
214 Winter RW, Burakoff R. How should we treat mild and moderate-severe Crohn's disease in 2017? A brief overview of available therapies. Expert Rev Gastroenterol Hepatol 2017;11:95-7. [PMID: 27900879 DOI: 10.1080/17474124.2017.1266935] [Reference Citation Analysis]
215 O'Connor A, Hamlin PJ, Taylor J, Selinger C, Scott N, Ford AC. Postoperative prophylaxis in Crohn's disease after intestinal resection: a retrospective analysis. Frontline Gastroenterol 2017;8:203-9. [PMID: 28839910 DOI: 10.1136/flgastro-2016-100749] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
216 Regueiro MD, Greer JB, Hanauer SB. Established Management Paradigms in IBD: Treatment Targets and Therapeutic Tools. Am J Gastroenterol Suppl 2016;3:8-16. [DOI: 10.1038/ajgsup.2016.16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
217 Iannone A, Ruospo M, Wong G, Principi M, Barone M, Strippoli GFM, Di Leo A. Chromoendoscopy for Surveillance in Ulcerative Colitis and Crohn's Disease: A Systematic Review of Randomized Trials. Clin Gastroenterol Hepatol. 2017;15:1684-1697.e11. [PMID: 27890853 DOI: 10.1016/j.cgh.2016.11.021] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 8.2] [Reference Citation Analysis]
218 Coskun M, Steenholdt C, de Boer NK, Nielsen OH. Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease. Clin Pharmacokinet. 2016;55:257-274. [PMID: 26255287 DOI: 10.1007/s40262-015-0316-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
219 Lian L, Stocchi L, Remzi FH, Shen B. Comparison of Endoscopic Dilation vs Surgery for Anastomotic Stricture in Patients With Crohn's Disease Following Ileocolonic Resection. Clin Gastroenterol Hepatol. 2017;15:1226-1231. [PMID: 27816758 DOI: 10.1016/j.cgh.2016.10.030] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 7.5] [Reference Citation Analysis]
220 Manne A, Khan AS, Malik TA. Obesity and Outcome of Crohn's Associated Perianal Fistula Surgery: A Case-Control Study. Gastroenterology Res 2015;8:291-5. [PMID: 27785311 DOI: 10.14740/gr698e] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
221 Herfarth HH, Kappelman MD, Long MD, Isaacs KL. Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases. Inflamm Bowel Dis 2016;22:224-33. [PMID: 26457382 DOI: 10.1097/MIB.0000000000000589] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
222 Ooi CJ, Makharia GK, Hilmi I, Gibson PR, Fock KM, Ahuja V, Ling KL, Lim WC, Thia KT, Wei SC, Leung WK, Koh PK, Gearry RB, Goh KL, Ouyang Q, Sollano J, Manatsathit S, de Silva HJ, Rerknimitr R, Pisespongsa P, Abu Hassan MR, Sung J, Hibi T, Boey CC, Moran N, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease. Asia Pacific Consensus Statements on Crohn's disease. Part 1: Definition, diagnosis, and epidemiology: (Asia Pacific Crohn's Disease Consensus--Part 1). J Gastroenterol Hepatol. 2016;31:45-55. [PMID: 25819140 DOI: 10.1111/jgh.12956] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 10.2] [Reference Citation Analysis]
223 Axelrad JE, Shah BJ. Clostridium difficile Infection in Inflammatory Bowel Disease: A Nursing-Based Quality Improvement Strategy. J Healthc Qual 2016;38:283-9. [DOI: 10.1097/jhq.0000000000000002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
224 Cai L, Zhang T, Wang C. Does a Higher Prevalence for Primary Diagnosis of Crohn's Disease Involve the Upper Gastrointestinal Tract? Inflamm Bowel Dis 2016;22:E32-3. [PMID: 27508515 DOI: 10.1097/MIB.0000000000000885] [Reference Citation Analysis]
225 Yvon S, Olier M, Leveque M, Jard G, Tormo H, Haimoud-Lekhal DA, Peter M, Eutamène H. Donkey milk consumption exerts anti-inflammatory properties by normalizing antimicrobial peptides levels in Paneth's cells in a model of ileitis in mice. Eur J Nutr 2018;57:155-66. [PMID: 27581119 DOI: 10.1007/s00394-016-1304-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
226 Kokoszko-bilska A, Sobkiewicz S, Fichna J. Inflammatory bowel diseases and reproductive health. Pharmacological Reports 2016;68:859-64. [DOI: 10.1016/j.pharep.2016.03.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
227 John ES, Katz K, Saxena M, Chokhavatia S, Katz S. Management of Inflammatory Bowel Disease in the Elderly. Curr Treat Options Gastroenterol. 2016;14:285-304. [PMID: 27387455 DOI: 10.1007/s11938-016-0099-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
228 Scott FI, Lichtenstein GR. Approach to the Patient with Mild Crohn’s Disease: a 2016 Update. Curr Gastroenterol Rep 2016;18. [DOI: 10.1007/s11894-016-0523-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
229 Tundia N, Kotze PG, Rojas Serrano J, Mendes de Abreu M, Skup M, Macaulay D, Signorovitch J, Chaves L, Chao J, Bao Y. Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn’s disease in Argentina, Brazil, Colombia, and Mexico. Journal of Medical Economics 2016;19:1187-99. [DOI: 10.1080/13696998.2016.1209508] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
230 Lui RNS, Ng SC. The Same Intestinal Inflammatory Disease despite Different Genetic Risk Factors in the East and West? Inflamm Intest Dis 2016;1:78-84. [PMID: 29922661 DOI: 10.1159/000446625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
231 Chhaya V, Saxena S, Cecil E, Subramanian V, Curcin V, Majeed A, Pollok RC. Steroid dependency and trends in prescribing for inflammatory bowel disease - a 20-year national population-based study. Aliment Pharmacol Ther 2016;44:482-94. [DOI: 10.1111/apt.13700] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
232 Schüle S, Rossel JB, Frey D, Biedermann L, Scharl M, Zeitz J, Freitas-Queiroz N, Pittet V, Vavricka SR, Rogler G, Misselwitz B; Swiss IBD cohort study. Prediction of low bone mineral density in patients with inflammatory bowel diseases. United European Gastroenterol J 2016;4:669-76. [PMID: 27733909 DOI: 10.1177/2050640616658224] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
233 Abdalla MI, Herfarth H. Budesonide for the treatment of ulcerative colitis. Expert Opin Pharmacother. 2016;17:1549-1559. [PMID: 27157244 DOI: 10.1080/14656566.2016.1183648] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
234 Griffey RT, Fowler KJ, Theilen A, Gutierrez A. Considerations in Imaging Among Emergency Department Patients With Inflammatory Bowel Disease. Ann Emerg Med 2017;69:587-99. [PMID: 27317304 DOI: 10.1016/j.annemergmed.2016.04.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
235 Sartor RB. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;43 Suppl 1:27-36. [PMID: 26618923 DOI: 10.1111/apt.13436] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 6.2] [Reference Citation Analysis]
236 Uranga JA, López-Miranda V, Lombó F, Abalo R. Food, nutrients and nutraceuticals affecting the course of inflammatory bowel disease. Pharmacol Rep 2016;68:816-26. [PMID: 27267792 DOI: 10.1016/j.pharep.2016.05.002] [Cited by in Crossref: 79] [Cited by in F6Publishing: 78] [Article Influence: 13.2] [Reference Citation Analysis]
237 R-grau MDC, Chaparro M, Mesonero F, Barreiro-de Acosta M, Castro L, Castro M, Domènech E, Mancenido N, Pérez-calle JL, Taxonera C, Barrio J, De Francisco R, Fernández-salgado E, Luzón L, Merino O, Oltra L, Saro C, Bermejo F, García-sánchez V, Ginard D, Gutiérrez A, Vera I, Antón R, Ber Y, Calvet X, Gisbert JP. Effectiveness of anti-TNFα drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNFα agent. Digestive and Liver Disease 2016;48:613-9. [DOI: 10.1016/j.dld.2016.02.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
238 Mullican KA, Francart SJ. The role of specialty pharmacy drugs in the management of inflammatory diseases. American Journal of Health-System Pharmacy 2016;73:821-30. [DOI: 10.2146/ajhp150727] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
239 Abhyankar A, Moss AC. Iron Replacement in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2015;21:1976-81. [PMID: 25844962 DOI: 10.1097/MIB.0000000000000386] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
240 Merkley SA, Beaulieu DB, Horst S, Duley C, Annis K, Nohl A, Schwartz DA. Use of Intravenous Immunoglobulin for Patients with Inflammatory Bowel Disease with Contraindications or Who Are Unresponsive to Conventional Treatments. Inflamm Bowel Dis. 2015;21:1854-1859. [PMID: 25993689 DOI: 10.1097/mib.0000000000000456] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
241 Ahmed O, Nguyen GC. Therapeutic challenges of managing inflammatory bowel disease in the elderly patient. Expert Rev Gastroenterol Hepatol 2016;10:1005-10. [PMID: 27087144 DOI: 10.1080/17474124.2016.1179579] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
242 Ahmed O, Rodrigues DM, Nguyen GC. Magnetic Resonance Imaging of the Small Bowel in Crohn's Disease: A Systematic Review and Meta-Analysis. Can J Gastroenterol Hepatol 2016;2016:7857352. [PMID: 27446869 DOI: 10.1155/2016/7857352] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
243 Schlussel AT, Steele SR, Alavi K. Current challenges in the surgical management of Crohn's disease: a systematic review. Am J Surg. 2016;212:345-351. [PMID: 27182048 DOI: 10.1016/j.amjsurg.2015.12.027] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
244 Hahn L, Beggs A, Wahaib K, Kodali L, Kirkwood V. Vedolizumab: An integrin-receptor antagonist for treatment of Crohn's disease and ulcerative colitis. Am J Health Syst Pharm 2015;72:1271-8. [PMID: 26195652 DOI: 10.2146/ajhp140449] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
245 Guadagno E, Del Basso De Caro M, Del Prete E, D'Armiento FP, Campione S. Coexistence of Multiple Ileal Neuroendocrine Tumors and Idiopathic Myointimal Hyperplasia of Mesenteric Veins: Coincidence or Consequence? Case Report and Review of Literature. Int J Surg Pathol 2016;24:627-30. [PMID: 27069024 DOI: 10.1177/1066896916642289] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
246 Wang L, Cao Y, Gu HP, Ren H, Yang XY, Jia H. Crohn's disease with recurrent herpes zoster: A case report. Shijie Huaren Xiaohua Zazhi 2016; 24(10): 1618-1620 [DOI: 10.11569/wcjd.v24.i10.1618] [Reference Citation Analysis]
247 Olech E. Biosimilars: Rationale and current regulatory landscape. Seminars in Arthritis and Rheumatism 2016;45:S1-S10. [DOI: 10.1016/j.semarthrit.2016.01.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
248 Benmassaoud A, Xie X, AlYafi M, Theoret Y, Bitton A, Afif W, Bessissow T. Thiopurines in the Management of Crohn's Disease: Safety and Efficacy Profile in Patients with Normal TPMT Activity-A Retrospective Study. Can J Gastroenterol Hepatol 2016;2016:1034834. [PMID: 27446822 DOI: 10.1155/2016/1034834] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
249 Hagen JW, Swoger JM, Grandinetti LM. Cutaneous manifestations of crohn disease. Dermatol Clin. 2015;33:417-431. [PMID: 26143422 DOI: 10.1016/j.det.2015.03.007] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
250 Kaffenberger BH, Kaffenberger JA, Wong H, Jarjour W, Levin D, Bechtel MA. Magnetic resonance elastography and transient elastography as non-invasive analyses for liver fibrosis: can they obviate the need for liver biopsy in psoriasis patients treated with methotrexate? Int J Dermatol. 2015;54:752-756. [PMID: 26108262 DOI: 10.1111/ijd.12923] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
251 Kim C, Park SH, Yang SK, Ye BD, Park SH, Lee JS, Kim HJ, Kim AY, Ha HK. Endoscopic Complete Remission of Crohn Disease After Anti-Tumor Necrosis Factor-α Therapy: CT Enterographic Findings and Their Clinical Implications. AJR Am J Roentgenol 2016;206:1208-16. [PMID: 26998628 DOI: 10.2214/AJR.15.15256] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
252 Park SH. DWI at MR Enterography for Evaluating Bowel Inflammation in Crohn Disease. AJR Am J Roentgenol. 2016;207:40-48. [PMID: 26959382 DOI: 10.2214/ajr.15.15862] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
253 Abraham B, Wolf D, Regueiro M, Randall C, Kosutic G, Spearman M, Coarse J, Hasan I, Loftus E. P-098 Serious Infections in Patients Treated with Certolizumab Pegol with or Without Corticosteroids: Pooled Safety Data from 15 Clinical Trials. Inflammatory Bowel Diseases 2016;22:S40. [DOI: 10.1097/01.mib.0000480203.44901.5d] [Reference Citation Analysis]
254 Peyrin-biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel J, Hanauer SB, Rycroft B. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clinical Gastroenterology and Hepatology 2016;14:348-354.e17. [DOI: 10.1016/j.cgh.2015.06.001] [Cited by in Crossref: 220] [Cited by in F6Publishing: 198] [Article Influence: 36.7] [Reference Citation Analysis]
255 Assa A, Avni I, Ben-bassat O, Niv Y, Shamir R. Practice Variations in the Management of Inflammatory Bowel Disease Between Pediatric and Adult Gastroenterologists. Journal of Pediatric Gastroenterology & Nutrition 2016;62:372-7. [DOI: 10.1097/mpg.0000000000000943] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
256 Chang MI, Cohen BL, Greenstein AJ. A review of the impact of biologics on surgical complications in Crohn's disease. Inflamm Bowel Dis 2015;21:1472-7. [PMID: 25811432 DOI: 10.1097/MIB.0000000000000362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
257 Parian A, Ha CY. Older age and steroid use are associated with increasing polypharmacy and potential medication interactions among patients with inflammatory bowel disease. Inflamm Bowel Dis 2015;21:1392-400. [PMID: 25856768 DOI: 10.1097/MIB.0000000000000391] [Cited by in Crossref: 9] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
258 Lee NS, Pola S, Groessl EJ, Rivera-Nieves J, Ho SB. Opportunities for Improvement in the Care of Patients Hospitalized for Inflammatory Bowel Disease-Related Colitis. Dig Dis Sci 2016;61:1003-12. [PMID: 26860508 DOI: 10.1007/s10620-016-4046-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
259 Sun J, Shen X, Dong J, Wang H, Zuo L, Zhao J, Zhu W, Li Y, Gong J, Li J. Tripterygium wilfordii Hook F as Maintenance Treatment for Crohn's Disease. Am J Med Sci 2015;350:345-51. [PMID: 26473333 DOI: 10.1097/MAJ.0000000000000591] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
260 Blagec K, Romagnoli KM, Boyce RD, Samwald M. Examining perceptions of the usefulness and usability of a mobile-based system for pharmacogenomics clinical decision support: a mixed methods study. PeerJ 2016;4:e1671. [PMID: 26925317 DOI: 10.7717/peerj.1671] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
261 Nimmons D, Limdi JK. Elderly patients and inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2016; 7(1): 51-65 [PMID: 26855812 DOI: 10.4292/wjgpt.v7.i1.51] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
262 Con D, De Cruz P. Mobile Phone Apps for Inflammatory Bowel Disease Self-Management: A Systematic Assessment of Content and Tools. JMIR Mhealth Uhealth. 2016;4:e13. [PMID: 26831935 DOI: 10.2196/mhealth.4874] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 7.2] [Reference Citation Analysis]
263 Qiu Y, Mao R, Zhang SH, Li MY, Guo J, Chen BL, He Y, Zeng ZR, Chen MH. Safety Profile of Thiopurines in Crohn Disease: Analysis of 893 Patient-Years Follow-Up in a Southern China Cohort. Medicine (Baltimore). 2015;94:e1513. [PMID: 26469893 DOI: 10.1097/md.0000000000001513] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
264 Tarabar D, Hirsch A, Rubin DT. Vedolizumab in the treatment of Crohn’s disease. Expert Review of Gastroenterology & Hepatology 2015;10:283-90. [DOI: 10.1586/17474124.2016.1135051] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
265 Dutta AK, Chacko A. Influence of environmental factors on the onset and course of inflammatory bowel disease. World J Gastroenterol 2016; 22(3): 1088-1100 [PMID: 26811649 DOI: 10.3748/wjg.v22.i3.1088] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
266 Wędrychowicz A, Zając A, Tomasik P. Advances in nutritional therapy in inflammatory bowel diseases: Review. World J Gastroenterol 2016; 22(3): 1045-1066 [PMID: 26811646 DOI: 10.3748/wjg.v22.i3.1045] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 53] [Article Influence: 11.2] [Reference Citation Analysis]
267 Owczarek D, Rodacki T, Domagała-Rodacka R, Cibor D, Mach T. Diet and nutritional factors in inflammatory bowel diseases. World J Gastroenterol 2016; 22(3): 895-905 [PMID: 26811635 DOI: 10.3748/wjg.v22.i3.895] [Cited by in CrossRef: 127] [Cited by in F6Publishing: 102] [Article Influence: 21.2] [Reference Citation Analysis]
268 Nitzan O, Elias M, Peretz A, Saliba W. Role of antibiotics for treatment of inflammatory bowel disease. World J Gastroenterol 2016; 22(3): 1078-1087 [PMID: 26811648 DOI: 10.3748/wjg.v22.i3.1078] [Cited by in CrossRef: 128] [Cited by in F6Publishing: 107] [Article Influence: 21.3] [Reference Citation Analysis]
269 Cravo M. RDW as a Surrogate Marker for Active Crohn's Disease: Potential Utility. GE Port J Gastroenterol 2016;23:1-3. [PMID: 28868422 DOI: 10.1016/j.jpge.2015.12.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
270 Regalia K, Shelton A, Berry G, Triadafilopoulos G, Cartwright CA. Pulmonary Crohn's Disease. Dig Dis Sci 2017;62:64-7. [PMID: 26685911 DOI: 10.1007/s10620-015-3993-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
271 Krishnarao A, de Leon L, Bright R, Moniz H, Law M, Leleiko N, Sands BE, Merrick M, Shapiro J, Wallenstein S. Testing for Clostridium difficile in patients newly diagnosed with inflammatory bowel disease in a community setting. Inflamm Bowel Dis. 2015;21:564-569. [PMID: 25581825 DOI: 10.1097/mib.0000000000000309] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
272 Huoponen S, Blom M. A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel Diseases. PLoS One 2015;10:e0145087. [PMID: 26675292 DOI: 10.1371/journal.pone.0145087] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
273 Sorita A, Thongprayoon C, Ahmed A, Bates RE, Ratelle JT, Rieck KM, Devalapalli AP, Issa M, Shah RM, Lalama MA, Wang Z, Murad MH, Kashiwagi DT. Frequency and Appropriateness of Fasting Orders in the Hospital. Mayo Clin Proc 2015;90:1225-32. [PMID: 26355400 DOI: 10.1016/j.mayocp.2015.07.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
274 Johnson SL, Palta M, Bartels CM, Thorpe CT, Weiss JM, Smith MA. Examining systemic steroid Use in older inflammatory bowel disease patients using hurdle models: a cohort study. BMC Pharmacol Toxicol 2015;16:34. [PMID: 26643112 DOI: 10.1186/s40360-015-0034-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
275 Barkmeier DT, Dillman JR, Al-Hawary M, Heider A, Davenport MS, Smith EA, Adler J. MR enterography-histology comparison in resected pediatric small bowel Crohn disease strictures: can imaging predict fibrosis? Pediatr Radiol. 2016;46:498-507. [PMID: 26638000 DOI: 10.1007/s00247-015-3506-6] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 6.7] [Reference Citation Analysis]
276 Urbanska AM, Karagiannis ED, Au AS, Dai SY, Mozafari M, Prakash S. What's Next for Gastrointestinal Disorders: No Needles? J Control Release 2016;221:48-61. [PMID: 26646543 DOI: 10.1016/j.jconrel.2015.11.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
277 Moreau J, Mas E. Drug resistance in inflammatory bowel diseases. Curr Opin Pharmacol. 2015;25:56-61. [PMID: 26645664 DOI: 10.1016/j.coph.2015.11.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
278 Hirten R, Sultan K, Thomas A, Bernstein DE. Hepatic manifestations of non-steroidal inflammatory bowel disease therapy. World J Hepatol 2015; 7(27): 2716-2728 [PMID: 26644815 DOI: 10.4254/wjh.v7.i27.2716] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
279 Danese S, Grisham M, Hodge J, Telliez JB. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol. 2016;310:G155-G162. [PMID: 26608188 DOI: 10.1152/ajpgi.00311.2015] [Cited by in Crossref: 97] [Cited by in F6Publishing: 88] [Article Influence: 13.9] [Reference Citation Analysis]
280 Park JR, Pfeil SA. Primary Care of the Patient with Inflammatory Bowel Disease. Med Clin North Am 2015;99:969-87. [PMID: 26320042 DOI: 10.1016/j.mcna.2015.05.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
281 Trivedi I, Hanauer SB. Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. Expert Opin Drug Saf 2015;14:1915-34. [PMID: 26559664 DOI: 10.1517/14740338.2015.1108961] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
282 Xu Z, Davis HM, Zhou H. Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety. J Clin Pharmacol 2015;55 Suppl 3:S60-74. [PMID: 25707965 DOI: 10.1002/jcph.380] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
283 González-Lama Y, Suárez C, González-Partida I, Calvo M, Matallana V, de la Revilla J, Magaz M, Bernardo C, Agudo B, Ibarrola P, Relea L, Arévalo J, Vera MI, Abreu L. Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn's Disease: A Retrospective Cohort Study. J Crohns Colitis 2016;10:55-60. [PMID: 26520164 DOI: 10.1093/ecco-jcc/jjv187] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
284 Zhang P, Minardi LM, Kuenstner JT, Kruzelock R. Mycobacterium avium subspecies hominissuis in Crohn's disease: a case report. Gastroenterol Rep (Oxf) 2017;5:316-9. [PMID: 26510454 DOI: 10.1093/gastro/gov054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
285 Chang S, Malter L, Hudesman D. Disease monitoring in inflammatory bowel disease. World J Gastroenterol 2015; 21(40): 11246-11259 [PMID: 26523100 DOI: 10.3748/wjg.v21.i40.11246] [Cited by in CrossRef: 92] [Cited by in F6Publishing: 74] [Article Influence: 13.1] [Reference Citation Analysis]
286 Qiu Y, Chen BL, Mao R, Zhang SH, He Y, Zeng ZR, Chen MH. Endoscopy Assessment at 1-Year Identifies Long-Term Responders to Thiopurines Maintenance Therapy in Patients With Crohn's Disease. Medicine (Baltimore) 2015;94:e1204. [PMID: 26252278 DOI: 10.1097/MD.0000000000001204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
287 Qiu Y, Chen BL, Mao R, Zhang SH, He Y, Zeng ZR, Chen MH. Early Thiopurines Versus Conventional Step-Care Therapy for Modifying the Disease Course of Early Crohn's Disease: A Tertiary Referral Center Cohort Study. Medicine (Baltimore) 2015;94:e1148. [PMID: 26252273 DOI: 10.1097/MD.0000000000001148] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
288 Boland BS, Boyle DL, Sandborn WJ, Firestein GS, Levesque BG, Hillman J, Zhang B, Proudfoot J, Eckmann L, Ernst PB, Rivera-Nieves J, Pola S, Copur-Dahi N, Zou G, Chang JT. Validation of gene expression biomarker analysis for biopsy-based clinical trials in Crohn's disease. Inflamm Bowel Dis 2015;21:323-30. [PMID: 25545378 DOI: 10.1097/MIB.0000000000000264] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
289 Kalman RS, Hartshorn K, Farraye FA. Does a personal or family history of malignancy preclude the use of immunomodulators and biologics in IBD. Inflamm Bowel Dis 2015;21:428-35. [PMID: 25251059 DOI: 10.1097/MIB.0000000000000211] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
290 Qazi T, Shah B, El-Dib M, Farraye FA. The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2016;61:589-96. [PMID: 26441281 DOI: 10.1007/s10620-015-3893-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
291 Taleban S, Van Oijen MG, Vasiliauskas EA, Fleshner PR, Shen B, Ippoliti AF, Targan SR, Melmed GY. Colectomy with Permanent End Ileostomy Is More Cost-Effective than Ileal Pouch-Anal Anastomosis for Crohn's Colitis. Dig Dis Sci 2016;61:550-9. [PMID: 26434930 DOI: 10.1007/s10620-015-3886-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
292 Arntzenius A, van Galen L. Budesonide-related adrenal insufficiency. BMJ Case Rep 2015;2015:bcr2015212216. [PMID: 26430235 DOI: 10.1136/bcr-2015-212216] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
293 Mcnamara KL, Aronson MD, Cohen Z. Is there a role for prophylactic colectomy in Lynch syndrome patients with inflammatory bowel disease? Int J Colorectal Dis 2016;31:9-13. [DOI: 10.1007/s00384-015-2398-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
294 Wallenhorst T, Brochard C, Bretagne J, Bouguen G, Siproudhis L. Crohn’s disease: is there any link between anal and luminal phenotypes? Int J Colorectal Dis 2016;31:307-11. [DOI: 10.1007/s00384-015-2390-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
295 Bryant RV, Brain O, Travis SP. Conventional drug therapy for inflammatory bowel disease. Scand J Gastroenterol. 2015;50:90-112. [PMID: 25523560 DOI: 10.3109/00365521.2014.968864] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 5.7] [Reference Citation Analysis]
296 Lawlor R, Glanc P, Szentgyorgyi E, Khalili K. High-Resolution Ultrasound Characterization of Colonic Lymphoid Hyperplasia in a Case of Active Crohn Colitis. Ultrasound Q 2015;31:e1-4. [PMID: 26366701 DOI: 10.1097/RUQ.0000000000000202] [Reference Citation Analysis]
297 Lee J, Clarke K. Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma—challenges in management. Int J Colorectal Dis 2015;30:1595-602. [DOI: 10.1007/s00384-015-2344-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
298 Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12:537-545. [PMID: 26284562 DOI: 10.1038/nrgastro.2015.135] [Cited by in Crossref: 193] [Cited by in F6Publishing: 187] [Article Influence: 27.6] [Reference Citation Analysis]
299 Kyriacou A, McLaughlin J, Syed AA. Thyroid disorders and gastrointestinal and liver dysfunction: A state of the art review. Eur J Intern Med 2015;26:563-71. [PMID: 26260744 DOI: 10.1016/j.ejim.2015.07.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
300 Martin CS, Blaga C, Lambrescu IM, Fierbințeanu-Braticevici C, Fica S. Iatrogenic Cushing's syndrome related to the interaction between oral budesonide with fluvoxamine: a case report. J Clin Pharm Ther 2015;40:612-4. [PMID: 26249140 DOI: 10.1111/jcpt.12312] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
301 Patel N, Suarez LD, Kapur S, Bielory L. Hereditary Angioedema and Gastrointestinal Complications: An Extensive Review of the Literature. Case Reports Immunol 2015;2015:925861. [PMID: 26339513 DOI: 10.1155/2015/925861] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
302 Delmondes LM, Nunes MO, Azevedo AR, Oliveira MM, Coelho LE, Torres-Neto JD. Clinical and Sociodemographic Aspects of Inflammatory Bowel Disease Patients. Gastroenterology Res. 2015;8:207-215. [PMID: 27785298 DOI: 10.14740/gr649w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
303 Park KT, Colletti RB, Rubin DT, Sharma BK, Thompson A, Krueger A. Health Insurance Paid Costs and Drivers of Costs for Patients With Crohn's Disease in the United States. Am J Gastroenterol 2016;111:15-23. [PMID: 26195179 DOI: 10.1038/ajg.2015.207] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 7.4] [Reference Citation Analysis]
304 Caso F, Galozzi P, Costa L, Sfriso P, Cantarini L, Punzi L. Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease. RMD Open 2015;1:e000097. [PMID: 26509073 DOI: 10.1136/rmdopen-2015-000097] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 9.6] [Reference Citation Analysis]
305 Okafor PN, Farraye FA, Okafor AT, Erim DO. Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn's Disease. Dig Dis Sci 2015;60:3743-55. [PMID: 26177704 DOI: 10.1007/s10620-015-3796-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
306 Taleban S. Challenges in the Diagnosis and Management of Inflammatory Bowel Disease in the Elderly. Curr Treat Options Gastro 2015;13:275-86. [DOI: 10.1007/s11938-015-0059-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
307 Sheth T, Pitchumoni CS, Das KM. Management of Musculoskeletal Manifestations in Inflammatory Bowel Disease. Gastroenterol Res Pract. 2015;2015:387891. [PMID: 26170832 DOI: 10.1155/2015/387891] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
308 van Deen WK, van Oijen MG, Myers KD, Centeno A, Howard W, Choi JM, Roth BE, McLaughlin EM, Hollander D, Wong-Swanson B, Sack J, Ong MK, Ha CY, Esrailian E, Hommes DW. A nationwide 2010-2012 analysis of U.S. health care utilization in inflammatory bowel diseases. Inflamm Bowel Dis. 2014;20:1747-1753. [PMID: 25137415 DOI: 10.1097/mib.0000000000000139] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 7.3] [Reference Citation Analysis]
309 Frederiksen MT, Ainsworth MA, Brynskov J, Thomsen OO, Bendtzen K, Steenholdt C. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. Inflamm Bowel Dis. 2014;20:1714-1721. [PMID: 25069030 DOI: 10.1097/mib.0000000000000138] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 10.0] [Reference Citation Analysis]
310 Yoshino T, Matsuura M, Minami N, Yamada S, Honzawa Y, Kimura M, Koshikawa Y, Madian A, Toyonaga T, Nakase H. Efficacy of Thiopurines in Biologic-Naive Japanese Patients With Crohn's Disease: A Single-Center Experience. Intest Res 2015;13:266-73. [PMID: 26131002 DOI: 10.5217/ir.2015.13.3.266] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
311 Flores C, Francesconi CF, Meurer L. Quantitative assessment of CD30+ lymphocytes and eosinophils for the histopathological differential diagnosis of inflammatory bowel disease. J Crohns Colitis 2015;9:763-8. [PMID: 26048916 DOI: 10.1093/ecco-jcc/jjv097] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
312 Erim DO, Mahendraratnam N, Okafor PN, Wheeler SB. The Value of Vedolizumab as Rescue Therapy in Moderate-Severe Crohn's Disease Patients with Adalimumab Non-response in the USA. J Crohns Colitis 2015;9:669-75. [PMID: 25987351 DOI: 10.1093/ecco-jcc/jjv090] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
313 Lahad A, Weiss B. Current therapy of pediatric Crohn’s disease. World J Gastrointest Pathophysiol 2015; 6(2): 33-42 [PMID: 25977836 DOI: 10.4291/wjgp.v6.i2.33] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
314 Randall CW, Vizuete JA, Martinez N, Alvarez JJ, Garapati KV, Malakouti M, Taboada CM. From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease. Therap Adv Gastroenterol 2015;8:143-59. [PMID: 25949527 DOI: 10.1177/1756283X15576462] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
315 Poulakos M, Machin JD, Pauly J, Grace Y. Vedolizumab: A New Opponent in the Battle Against Crohn's Disease and Ulcerative Colitis. J Pharm Pract 2016;29:503-15. [PMID: 25952593 DOI: 10.1177/0897190015579610] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
316 Bennett AL, Munkholm P, Andrews JM. Tools for primary care management of inflammatory bowel disease: Do they exist? World J Gastroenterol 2015; 21(15): 4457-4465 [PMID: 25914455 DOI: 10.3748/wjg.v21.i15.4457] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
317 Li Y, Zuo L, Zhu W, Gong J, Zhang W, Gu L, Guo Z, Cao L, Li N, Li J. Role of exclusive enteral nutrition in the preoperative optimization of patients with Crohn's disease following immunosuppressive therapy. Medicine (Baltimore). 2015;94:e478. [PMID: 25654387 DOI: 10.1097/md.0000000000000478] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
318 Taleban S, Colombel JF, Mohler MJ, Fain MJ. Inflammatory bowel disease and the elderly: a review. J Crohns Colitis. 2015;9:507-515. [PMID: 25870198 DOI: 10.1093/ecco-jcc/jjv059] [Cited by in Crossref: 71] [Cited by in F6Publishing: 72] [Article Influence: 10.1] [Reference Citation Analysis]
319 Tanida S, Ozeki K, Mizoshita T, Tsukamoto H, Katano T, Kataoka H, Kamiya T, Joh T. Managing refractory Crohn's disease: challenges and solutions. Clin Exp Gastroenterol 2015;8:131-40. [PMID: 25914555 DOI: 10.2147/CEG.S61868] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
320 Yang C, Singh P, Singh H, Le ML, El-Matary W. Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41:1079-1093. [PMID: 25858208 DOI: 10.1111/apt.13181] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
321 Echarri A, Ollero V, Barreiro-de Acosta M, Fernández-villaverde A, Hernández V, Lorenzo A, Pereira S, Carpio D, Castro J. Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn’s disease: predictors of efficacy in clinical practice. European Journal of Gastroenterology & Hepatology 2015;27:430-5. [DOI: 10.1097/meg.0000000000000296] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
322 Friedman S. Sexual Dysfunction in Inflammatory Bowel Disease: “Donʼt Ask, Donʼt Tell” Doesnʼt Work. Inflammatory Bowel Diseases 2015;21:948-50. [DOI: 10.1097/mib.0000000000000259] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
323 Shah ED, Siegel CA, Chong K, Melmed GY. Patients with Crohn’s Disease Are More Likely to Remain on Biologics than Immunomodulators: A Meta-Analysis of Treatment Durability. Dig Dis Sci 2015;60:2408-18. [DOI: 10.1007/s10620-015-3618-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
324 Sands K, Jansen R, Zaslau S, Greenwald D. Review article: the safety of therapeutic drugs in male inflammatory bowel disease patients wishing to conceive. Aliment Pharmacol Ther 2015;41:821-34. [DOI: 10.1111/apt.13142] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 6.7] [Reference Citation Analysis]
325 Hauso Ø, Martinsen TC, Waldum H. 5-Aminosalicylic acid, a specific drug for ulcerative colitis. Scandinavian Journal of Gastroenterology 2015;50:933-41. [DOI: 10.3109/00365521.2015.1018937] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
326 Michelassi F, Sultan S. Surgical treatment of complex small bowel Crohn disease. Ann Surg. 2014;260:230-235. [PMID: 24743631 DOI: 10.1097/SLA.0000000000000697] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
327 Willrich MA, Murray DL, Snyder MR. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. Translational Research 2015;165:270-82. [DOI: 10.1016/j.trsl.2014.09.006] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 10.6] [Reference Citation Analysis]
328 Kane S. If variety is the spice of life, we need to rethink our recipe: variation in inflammatory bowel disease practice among tertiary centers. Clin Gastroenterol Hepatol 2015;13:1201-3. [PMID: 25638587 DOI: 10.1016/j.cgh.2015.01.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
329 Ha C, Mathur J, Kornbluth A. Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2015;9:497-505. [PMID: 25600263 DOI: 10.1586/17474124.2015.983079] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
330 Tontini GE, Vecchi M, Pastorelli L, Neurath MF, Neumann H. Differential diagnosis in inflammatory bowel disease colitis: State of the art and future perspectives. World J Gastroenterol 2015; 21(1): 21-46 [PMID: 25574078 DOI: 10.3748/wjg.v21.i1.21] [Cited by in CrossRef: 109] [Cited by in F6Publishing: 91] [Article Influence: 15.6] [Reference Citation Analysis]
331 Nguyen GC, Devlin SM, Afif W, Bressler B, Gruchy SE, Kaplan GG, Oliveira L, Plamondon S, Seow CH, Williams C. Defining quality indicators for best-practice management of inflammatory bowel disease in Canada. Can J Gastroenterol Hepatol. 2014;28:275-285. [PMID: 24839622 DOI: 10.1155/2014/941245] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 5.6] [Reference Citation Analysis]
332 Lee A, Kanuri N, Zhang Y, Sayuk GS, Li E, Ciorba MA. IDO1 and IDO2 non-synonymous gene variants: correlation with crohn's disease risk and clinical phenotype. PLoS One 2014;9:e115848. [PMID: 25541686 DOI: 10.1371/journal.pone.0115848] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
333 Iskandar HN, Cassell B, Kanuri N, Gyawali CP, Gutierrez A, Dassopoulos T, Ciorba MA, Sayuk GS. Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease. J Clin Gastroenterol 2014;48:423-9. [PMID: 24406434 DOI: 10.1097/MCG.0000000000000049] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
334 Affronti A, Orlando A, Cottone M. An update on medical management on Crohn’s disease. Expert Opin Pharmacother. 2015;16:63-78. [PMID: 25418125 DOI: 10.1517/14656566.2015.981525] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
335 Lopez A, Beaugerie L, Peyrin-Biroulet L. Thiopurines and myeloid disorders: is more caution needed when treating inflammatory bowel disease patients? Expert Rev Clin Immunol 2014;10:1563-5. [PMID: 25362886 DOI: 10.1586/1744666X.2014.977261] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
336 Vidigal FM, de Souza GS, Chebli LA, da Rocha Ribeiro TC, Furtado MC, Castro AC, Pinto AL, do Valle Pinheiro B, de Lima Pace FH, Machado de Oliveira J, de Oliveira Zanini KA, Gaburri PD, Zanini A, Ribeiro LC, Chebli JM. Azathioprine is more effective than mesalazine at preventing recurrent bowel obstruction in patients with ileocecal Crohn's disease. Med Sci Monit 2014;20:2165-70. [PMID: 25370731 DOI: 10.12659/MSM.890975] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
337 Hindryckx P, Baert F, Hart A, Armuzzi A, Panès J, Peyrin-biroulet L. Clinical trials in luminal Crohn's disease: A historical perspective. Journal of Crohn's and Colitis 2014;8:1339-50. [DOI: 10.1016/j.crohns.2014.04.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
338 Akobeng AA, Sandborn WJ, Bickston SJ, Chande N, Shackelton LM, Nelson S, Feagan BG. Tumor Necrosis Factor-Alpha Antagonists Twenty Years Later: What Do Cochrane Reviews Tell Us? Inflammatory Bowel Diseases 2014;20:2132-41. [DOI: 10.1097/mib.0000000000000218] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
339 Zhu W, Li Y, Gong J, Zuo L, Zhang W, Cao L, Gu L, Guo Z, Li N, Li J. Tripterygium wilfordii Hook. f. versus azathioprine for prevention of postoperative recurrence in patients with Crohn's disease: a randomized clinical trial. Dig Liver Dis 2015;47:14-9. [PMID: 25445405 DOI: 10.1016/j.dld.2014.09.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
340 De Felice KM, Novotna M, Enders FT, Faubion WA, Tremaine WJ, Kantarci OH, Raffals LE. Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patients. Aliment Pharmacol Ther 2015;41:99-107. [PMID: 25348720 DOI: 10.1111/apt.12997] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
341 Friedman AB, Sparrow MP, Gibson PR. The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disorders. Int J Rheum Dis 2014;17:132-41. [PMID: 24618304 DOI: 10.1111/1756-185X.12204] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
342 Jiang X, Asbach P, Hamm B, Xu K, Banzer J. MR imaging of distal ileal and colorectal chronic inflammatory bowel disease--diagnostic accuracy of 1.5 T and 3 T MRI compared to colonoscopy. Int J Colorectal Dis 2014;29:1541-50. [PMID: 25339134 DOI: 10.1007/s00384-014-2037-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
343 Kerman DH, Deshpande AR. Gut microbiota and inflammatory bowel disease: the role of antibiotics in disease management. Postgrad Med. 2014;126:7-19. [PMID: 25141239 DOI: 10.3810/pgm.2014.07.2779] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
344 Saha S, Zhao YQ, Shah SA, Esposti SD, Lidofsky S, Salih S, Bright R, Law M, Moniz H, Flowers N, Merrick M, Sands BE. Menstrual cycle changes in women with inflammatory bowel disease: a study from the ocean state Crohn's and colitis area registry. Inflamm Bowel Dis 2014;20:534-40. [PMID: 24451220 DOI: 10.1097/01.MIB.0000441347.94451.cf] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
345 Sánchez-Montes C, Ortiz V, Bastida G, Rodríguez E, Yago M, Beltrán B, Aguas M, Iborra M, Garrigues V, Ponce J, Nos P. Small intestinal bacterial overgrowth in inactive Crohn’s disease: Influence of thiopurine and biological treatment. World J Gastroenterol 2014; 20(38): 13999-14003 [PMID: 25320539 DOI: 10.3748/wjg.v20.i38.13999] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
346 Nowakowski AC. Chronic inflammation and quality of life in older adults: a cross-sectional study using biomarkers to predict emotional and relational outcomes. Health Qual Life Outcomes 2014;12:141. [PMID: 25260501 DOI: 10.1186/s12955-014-0141-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.5] [Reference Citation Analysis]
347 Augustine JM, Lee JK, Armstrong EP. Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease. Expert Rev Pharmacoecon Outcomes Res 2014;14:599-609. [PMID: 25209304 DOI: 10.1586/14737167.2014.957680] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
348 Smith MA, Mohammad RA. Vedolizumab: An α 4 β 7 Integrin Inhibitor for Inflammatory Bowel Diseases. Ann Pharmacother 2014;48:1629-35. [DOI: 10.1177/1060028014549799] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
349 Garros A, Siproudhis L, Tchoundjeu B, Rohou T, Brochard C, Wallenhorst T, Bretagne JF, Bouguen G. Magnetic resonance imaging and clinical assessments for perianal Crohn's disease: gain and limits. Dig Liver Dis 2014;46:1072-6. [PMID: 25192603 DOI: 10.1016/j.dld.2014.08.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
350 Vavricka SR, Radivojevic S, Manser CN, Frei P, Burri E, Fried M, Schoepfer A, Peyrin-Biroulet L, Michetti P, Rogler G, Biedermann L. Addressing current treatment challenges in Crohn's disease in real life: a physician's survey. Dig Liver Dis 2014;46:1066-71. [PMID: 25169961 DOI: 10.1016/j.dld.2014.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
351 Lee KM, Lee JM. Crohn's disease in Korea: past, present, and future. Korean J Intern Med 2014;29:558-70. [PMID: 25228829 DOI: 10.3904/kjim.2014.29.5.558] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
352 Brotherton CS, Taylor AG. Dietary fiber information for individuals with Crohn disease: reports of gastrointestinal effects. Gastroenterol Nurs 2013;36:320-7. [PMID: 24084130 DOI: 10.1097/SGA.0b013e3182a67a9a] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
353 Smart C, Selinger CP. The cost–effectiveness of infliximab in Crohn’s disease. Expert Review of Pharmacoeconomics & Outcomes Research 2014;14:589-98. [DOI: 10.1586/14737167.2014.950235] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
354 Levesque BG, Sandborn WJ, Ruel J, Feagan BG, Sands BE, Colombel JF. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology. 2015; 148:37-51.e1. [PMID: 25127678 DOI: 10.1053/j.gastro.2014.08.003] [Cited by in Crossref: 142] [Cited by in F6Publishing: 139] [Article Influence: 17.8] [Reference Citation Analysis]
355 Buckley JP, Cook SF, Allen JK, Kappelman MD. Prevalence of chronic narcotic use among children with inflammatory bowel disease. Clin Gastroenterol Hepatol 2015;13:310-315.e2. [PMID: 25117776 DOI: 10.1016/j.cgh.2014.07.057] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
356 Chiba M, Tsuda S, Tsuji T, Nakane K, Komatsu M, Miura Y, Ishida T, Shibahara T, Nishimoto T. Crohn's disease successfully treated with infliximab in a patient receiving hemodialysis: case report and review of the literature. Medicine (Baltimore) 2014;93:e54. [PMID: 25101989 DOI: 10.1097/MD.0000000000000054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
357 Nielsen OH, Coskun M, Steenholdt C, Rogler G. The role and advances of immunomodulator therapy for inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 2014;9:177-89. [DOI: 10.1586/17474124.2014.945914] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
358 Paul S, Wand M, Emerick GT, Richter JM. The role of latanoprost in an inflammatory bowel disease flare. Gastroenterol Rep (Oxf). 2014;2:232-234. [PMID: 25064174 DOI: 10.1093/gastro/gou044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
359 Ha CY. Medical management of inflammatory bowel disease in the elderly: balancing safety and efficacy. Clin Geriatr Med 2014;30:67-78. [PMID: 24267603 DOI: 10.1016/j.cger.2013.10.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
360 Singh S, Pardi DS. Update on anti-tumor necrosis factor agents in Crohn disease. Gastroenterol Clin North Am. 2014;43:457-478. [PMID: 25110253 DOI: 10.1016/j.gtc.2014.05.008] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
361 Vuitton L, Koch S, Peyrin-Biroulet L. Preventing postoperative recurrence in Crohn’s disease: what does the future hold? Drugs. 2013;73:1749-1759. [PMID: 24132799 DOI: 10.1007/s40265-013-0128-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
362 Dulai PS, Siegel CA. The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease. Gastroenterol Clin North Am 2014;43:525-41. [PMID: 25110257 DOI: 10.1016/j.gtc.2014.05.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
363 Jess T, Lopez A, Andersson M, Beaugerie L, Peyrin-Biroulet L. Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis. Clin Gastroenterol Hepatol. 2014;12:1793-1800.e1. [PMID: 24907505 DOI: 10.1016/j.cgh.2014.05.019] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 6.5] [Reference Citation Analysis]
364 Kittai A, Ali MA, Borum M. Herpes simplex virus blepharitis in a patient with Crohn's colitis. Am J Med 2014;127:e1-2. [PMID: 24613714 DOI: 10.1016/j.amjmed.2014.02.036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
365 Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Fallingborg J, Christensen LA, Pedersen G, Kjeldsen J, Jacobsen BA, Oxholm AS, Kjellberg J, Bendtzen K, Ainsworth MA. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 2014;63:919-27. [PMID: 23878167 DOI: 10.1136/gutjnl-2013-305279] [Cited by in Crossref: 329] [Cited by in F6Publishing: 312] [Article Influence: 41.1] [Reference Citation Analysis]
366 Judge J, Giordano BP, English J. Crohn's disease masquerading as an acute abdomen. J Pediatr Health Care 2014;28:444-50. [PMID: 24856054 DOI: 10.1016/j.pedhc.2014.03.003] [Reference Citation Analysis]
367 Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, D'Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014; 147: 618-627. e3. [PMID: 24859203 DOI: 10.1053/j.gastro.2014.05.008] [Cited by in Crossref: 391] [Cited by in F6Publishing: 399] [Article Influence: 48.9] [Reference Citation Analysis]
368 Nguyen TV, Vu DH, Nguyen TM, Lachaux A, Boulieu R. Exploring associations of 6-thioguanine nucleotide levels and other predictive factors with therapeutic response to azathioprine in pediatric patients with IBD using multilevel analysis. Inflamm Bowel Dis 2013;19:2404-10. [PMID: 24013359 DOI: 10.1097/MIB.0b013e3182a508c6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
369 Antunes O, Filippi J, Hébuterne X, Peyrin-Biroulet L. Treatment algorithms in Crohn’s - up, down or something else? Best Pract Res Clin Gastroenterol. 2014;28:473-483. [PMID: 24913386 DOI: 10.1016/j.bpg.2014.05.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
370 Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Ainsworth MA. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial. Am J Gastroenterol 2014;109:1055-64. [PMID: 24796769 DOI: 10.1038/ajg.2014.106] [Cited by in Crossref: 95] [Cited by in F6Publishing: 102] [Article Influence: 11.9] [Reference Citation Analysis]
371 Shergill AK, Farraye FA. Toward a consensus on endoscopic surveillance of patients with colonic inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2014;24:469-481. [PMID: 24975537 DOI: 10.1016/j.giec.2014.03.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
372 Gupta S, Shen B. Bone loss in patients with the ileostomy and ileal pouch for inflammatory bowel disease. Gastroenterol Rep (Oxf). 2013;1:159-165. [PMID: 24759961 DOI: 10.1093/gastro/got030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
373 Ong DE, Kamm MA, Hartono JL, Lust M. Addition of thiopurines can recapture response in patients with Crohn’s disease who have lost response to anti-tumor necrosis factor monotherapy. J Gastroenterol Hepatol. 2013;28:1595-1599. [PMID: 23662928 DOI: 10.1111/jgh.12263] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
374 Häuser W, Moser G, Klose P, Mikocka-Walus A. Psychosocial issues in evidence-based guidelines on inflammatory bowel diseases: A review. World J Gastroenterol 2014; 20(13): 3663-3671 [PMID: 24707152 DOI: 10.3748/wjg.v20.i13.3663] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
375 Zhao LN, Li JY, Yu T, Chen GC, Yuan YH, Chen QK. 5-Aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: an updated meta-analysis. PLoS One. 2014;9:e94208. [PMID: 24710620 DOI: 10.1371/journal.pone.0094208] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
376 Burisch J, Pedersen N, Čuković-Čavka S, Brinar M, Kaimakliotis I, Duricova D, Shonová O, Vind I, Avnstrøm S, Thorsgaard N, Andersen V, Krabbe S, Dahlerup JF, Salupere R, Nielsen KR, Olsen J, Manninen P, Collin P, Tsianos EV, Katsanos KH, Ladefoged K, Lakatos L, Björnsson E, Ragnarsson G, Bailey Y, Odes S, Schwartz D, Martinato M, Lupinacci G, Milla M, De Padova A, D'Incà R, Beltrami M, Kupcinskas L, Kiudelis G, Turcan S, Tighineanu O, Mihu I, Magro F, Barros LF, Goldis A, Lazar D, Belousova E, Nikulina I, Hernandez V, Martinez-Ares D, Almer S, Zhulina Y, Halfvarson J, Arebi N, Sebastian S, Lakatos PL, Langholz E, Munkholm P; EpiCom-group. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut 2014;63:588-97. [PMID: 23604131 DOI: 10.1136/gutjnl-2013-304636] [Cited by in Crossref: 243] [Cited by in F6Publishing: 221] [Article Influence: 30.4] [Reference Citation Analysis]
377 Beswick L, Friedman AB, Sparrow MP. The role of thiopurine metabolite monitoring in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2014;8:383-92. [PMID: 24684593 DOI: 10.1586/17474124.2014.894878] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
378 Carvalho ATP, Esberard BC, Fróes RSB, Rapozo DCM, Grinman AB, Simão TA, Santos JCVC, Carneiro AJV, Ribeiro-Pinto LF, Souza HSP. Thiopurine-methyltransferase variants in inflammatory bowel disease: Prevalence and toxicity in Brazilian patients. World J Gastroenterol 2014; 20(12): 3327-3334 [PMID: 24696613 DOI: 10.3748/wjg.v20.i12.3327] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
379 Chebli JM, Gaburri PD, Chebli LA, da Rocha Ribeiro TC, Pinto AL, Ambrogini Júnior O, Damião AO. A guide to prepare patients with inflammatory bowel diseases for anti-TNF-α therapy. Med Sci Monit 2014;20:487-98. [PMID: 24667275 DOI: 10.12659/MSM.890331] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
380 O'Toole A, Winter D, Friedman S. Review article: the psychosexual impact of inflammatory bowel disease in male patients. Aliment Pharmacol Ther. 2014;39:1085-1094. [PMID: 24654697 DOI: 10.1111/apt.12720] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
381 Gallinger ZR, Weizman AV. Colorectal cancer in inflammatory bowel disease: a shift in risk? Expert Review of Anticancer Therapy 2014;14:847-56. [DOI: 10.1586/14737140.2014.895936] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
382 [DOI: 10.1117/12.2042795] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
383 Lopez A, Mounier M, Bouvier AM, Carrat F, Maynadié M, Beaugerie L, Peyrin-Biroulet L; CESAME Study Group. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease. Clin Gastroenterol Hepatol 2014;12:1324-9. [PMID: 24582568 DOI: 10.1016/j.cgh.2014.02.026] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 8.5] [Reference Citation Analysis]
384 Dassopoulos T, Sultan S, Falck-Ytter YT, Inadomi JM, Hanauer SB. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology. 2013;145:1464-78.e1-5. [PMID: 24267475 DOI: 10.1053/j.gastro.2013.10.046] [Cited by in Crossref: 92] [Cited by in F6Publishing: 85] [Article Influence: 11.5] [Reference Citation Analysis]
385 Vavricka SR, Schoepfer AM, Scharl M, Rogler G. Steroid Use in Crohn’s Disease. Drugs 2014;74:313-24. [DOI: 10.1007/s40265-014-0183-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
386 Yacoub JH, Oto A. New Magnetic Resonance Imaging Modalities for Crohn Disease. Magnetic Resonance Imaging Clinics of North America 2014;22:35-50. [DOI: 10.1016/j.mric.2013.07.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
387 Korelitz BI, Present DH. 6-Mercaptopurine/Azathioprine remains an important contributor in managing Crohn’s disease. J Crohns Colitis. 2014;8:735-738. [PMID: 24462321 DOI: 10.1016/j.crohns.2013.12.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
388 Min MX, Weinberg DI, Mccabe RP. Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use. J Clin Pharm Ther 2014;39:107-11. [DOI: 10.1111/jcpt.12125] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
389 Andrade TG, Fogaça HS, Elia CC, Pitrowsky MT, Souza HS. Crohn's disease activity assessed by Doppler sonography: the role of aortic flow parameters. Clinics (Sao Paulo) 2013;68:457-62. [PMID: 23778348 DOI: 10.6061/clinics/2013(04)04] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
390 Wallace KL, Zheng LB, Kanazawa Y, Shih DQ. Immunopathology of inflammatory bowel disease. World J Gastroenterol 2014; 20(1): 6-21 [PMID: 24415853 DOI: 10.3748/wjg.v20.i1.6] [Cited by in CrossRef: 311] [Cited by in F6Publishing: 289] [Article Influence: 38.9] [Reference Citation Analysis]
391 Trent RJ, Cheong PL, Chua EW, Kennedy MA. Progressing the utilisation of pharmacogenetics and pharmacogenomics into clinical care. Pathology 2013;45:357-70. [PMID: 23594690 DOI: 10.1097/PAT.0b013e328360b66e] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
392 Ha CY, Katz S. Clinical implications of ageing for the management of IBD. Nat Rev Gastroenterol Hepatol. 2014;11:128-138. [PMID: 24345890 DOI: 10.1038/nrgastro.2013.241] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
393 Longuet R, Willot S, Giniès J, Pélatan C, Breton E, Segura J, Bridoux L, Le Henaff G, Cagnard B, Jobert A, Cardonna J, Grimal I, Balençon M, Darviot E, Delaperrière N, Caldari D, Piloquet H, Dabadie A. Immunization status in children with inflammatory bowel disease. Eur J Pediatr. [DOI: 10.1007/s00431-013-2207-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
394 Yanai H, Shuster D, Calabrese E, Mlynarsky L, Tumuluri S, Cohen RD. The Incidence and Predictors of Lupus-like Reaction in Patients with IBD Treated with Anti-TNF Therapies: . Inflammatory Bowel Diseases 2013;19:2778-86. [DOI: 10.1097/01.mib.0000435435.91988.b6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
395 Wall CL, Day AS, Gearry RB. Use of exclusive enteral nutrition in adults with Crohn’s disease: A review. World J Gastroenterol 2013; 19(43): 7652-7660 [PMID: 24282355 DOI: 10.3748/wjg.v19.i43.7652] [Cited by in CrossRef: 88] [Cited by in F6Publishing: 83] [Article Influence: 9.8] [Reference Citation Analysis]
396 Orden RA, Timble H, Saini SS. Efficacy and safety of sulfasalazine in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2014;112:64-70. [PMID: 24331396 DOI: 10.1016/j.anai.2013.09.028] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
397 Zhang FM, Wang HG, Wang M, Cui BT, Fan ZN, Ji GZ. Fecal microbiota transplantation for severe enterocolonic fistulizing Crohn’s disease. World J Gastroenterol 2013; 19(41): 7213-7216 [PMID: 24222969 DOI: 10.3748/wjg.v19.i41.7213] [Cited by in CrossRef: 81] [Cited by in F6Publishing: 76] [Article Influence: 9.0] [Reference Citation Analysis]
398 Baran B, Karaca C. Practical medical management of Crohn's disease. ISRN Gastroenterol 2013;2013:208073. [PMID: 24307950 DOI: 10.1155/2013/208073] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
399 Bernheim O, Colombel JF, Ullman TA, Laharie D, Beaugerie L, Itzkowitz SH. The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut 2013;62:1523-8. [PMID: 23903238 DOI: 10.1136/gutjnl-2013-305300] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
400 Jo K, Hong Y, Jung YJ, Yoo B, Lee C, Kim Y, Yang S, Byeon J, Kim KJ, Ye BD, Lee S, Kim WS, Kim DS, Shim TS. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis. Respiratory Medicine 2013;107:1797-802. [DOI: 10.1016/j.rmed.2013.08.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
401 Tang DH, Harrington AR, Lee JK, Lin M, Armstrong EP. A Systematic Review of Economic Studies on Biological Agents Used to Treat Crohn’s Disease: . Inflammatory Bowel Diseases 2013;19:2673-94. [DOI: 10.1097/mib.0b013e3182916046] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
402 Weber NK, Bruining DH, Loftus EV, Tremaine WJ, Augustin JJ, Becker BD, Kammer PP, Harmsen WS, Zinsmeister AR, Pardi DS. Comparative Outcomes of Younger and Older Hospitalized Patients with Inflammatory Bowel Disease Treated with Corticosteroids: . Inflammatory Bowel Diseases 2013;19:2644-51. [DOI: 10.1097/01.mib.0000436961.08029.17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
403 Atreja A, Aggarwal A, Dwivedi S, Rieder F, Lopez R, Lashner BA, Brzezinski A, Vargo JJ, Shen B. Safety and efficacy of endoscopic dilation for primary and anastomotic Crohn's disease strictures. J Crohns Colitis 2014;8:392-400. [PMID: 24189349 DOI: 10.1016/j.crohns.2013.10.001] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 7.0] [Reference Citation Analysis]
404 Lee CK, Kim HS, Ye BD, Lee KM, Kim YS, Rhee SY, Kim HJ, Yang SK, Moon W, Koo JS, Lee SH, Seo GS, Park SJ, Choi CH, Jung SA, Hong SN, Im JP, Kim ES; Korean Association for the Study of Intestinal Diseases (KASID) Study. Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine. J Crohns Colitis 2014;8:384-91. [PMID: 24144611 DOI: 10.1016/j.crohns.2013.09.022] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
405 Weizman AV, Nguyen GC. Interventions and targets aimed at improving quality in inflammatory bowel disease ambulatory care. World J Gastroenterol 2013; 19(38): 6375-6382 [PMID: 24151356 DOI: 10.3748/wjg.v19.i38.6375] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
406 Montero-Meléndez T, Llor X, García-Planella E, Perretti M, Suárez A. Identification of novel predictor classifiers for inflammatory bowel disease by gene expression profiling. PLoS One. 2013;8:e76235. [PMID: 24155895 DOI: 10.1371/journal.pone.0076235] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
407 Moss AC, Brinks V, Carpenter JF. Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors. Aliment Pharmacol Ther. 2013;38:1188-1197. [PMID: 24118102 DOI: 10.1111/apt.12507] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 6.6] [Reference Citation Analysis]
408 Molander P, Sipponen T, Kemppainen H, Jussila A, Blomster T, Koskela R, Nissinen M, Rautiainen H, Kuisma J, Kolho K, Färkkilä M. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD. Journal of Crohn's and Colitis 2013;7:730-5. [DOI: 10.1016/j.crohns.2012.10.018] [Cited by in Crossref: 73] [Cited by in F6Publishing: 77] [Article Influence: 8.1] [Reference Citation Analysis]
409 Abraham NS, Richardson P, Castillo D, Kane SV. Dual Therapy With Infliximab and Immunomodulator Reduces One-Year Rates of Hospitalization and Surgery Among Veterans With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 2013;11:1281-7. [DOI: 10.1016/j.cgh.2013.06.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
410 Tontini GE, Vecchi M, Neurath MF, Neumann H. Advanced endoscopic imaging techniques in Crohn’s disease. J Crohns Colitis. 2014;8:261-269. [PMID: 24080247 DOI: 10.1016/j.crohns.2013.09.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
411 Moss AC. Prevention of postoperative recurrence of Crohn’s disease: what does the evidence support? Inflamm Bowel Dis. 2013;19:856-859. [PMID: 23446339 DOI: 10.1097/mib.0b013e3182802c21] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
412 Makanyanga JC, Pendsé D, Dikaios N, Bloom S, Mccartney S, Helbren E, Atkins E, Cuthbertson T, Punwani S, Forbes A, Halligan S, Taylor SA. Evaluation of Crohn’s disease activity: Initial validation of a magnetic resonance enterography global score (MEGS) against faecal calprotectin. Eur Radiol 2014;24:277-87. [DOI: 10.1007/s00330-013-3010-z] [Cited by in Crossref: 79] [Cited by in F6Publishing: 83] [Article Influence: 8.8] [Reference Citation Analysis]
413 Rogler G, Sandborn WJ. Is there still a role for thiopurines in Crohn's disease? Gastroenterology 2013;145:714-6. [PMID: 23973853 DOI: 10.1053/j.gastro.2013.08.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
414 Naganuma M, Nagahori M, Fujii T, Morio J, Saito E, Watanabe M. Poor recall of prior exposure to varicella zoster, rubella, measles, or mumps in patients with IBD. Inflamm Bowel Dis. 2013;19:418-422. [PMID: 22605673 DOI: 10.1002/ibd.23027] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
415 Kale-Pradhan PB, Zhao JJ, Palmer JR, Wilhelm SM. The role of antimicrobials in Crohn's disease. Expert Rev Gastroenterol Hepatol. 2013;7:281-288. [PMID: 23445237 DOI: 10.1586/egh.13.6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
416 Tabbaa M, Golubic M, Roizen MF, Bernstein AM. Docosahexaenoic acid, inflammation, and bacterial dysbiosis in relation to periodontal disease, inflammatory bowel disease, and the metabolic syndrome. Nutrients 2013;5:3299-310. [PMID: 23966110 DOI: 10.3390/nu5083299] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
417 Anupindi SA, Terreblanche O, Courtier J. Magnetic resonance enterography: inflammatory bowel disease and beyond. Magn Reson Imaging Clin N Am. 2013;21:731-750. [PMID: 24183523 DOI: 10.1016/j.mric.2013.05.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
418 Han J, Wang J, Wang JH. How to achieve deep remission in the treatment of inflammatory bowel disease. Journal of Traditional Chinese Medicine 2013;33:549-52. [DOI: 10.1016/s0254-6272(13)60164-8] [Reference Citation Analysis]
419 Abraham NS, Richardson P, Castillo D, Kane S. WITHDRAWN: Dual Therapy With Infliximab and Immunomodulator Reduces 1-Year Rates of Hospitalization and Surgery Among Veterans With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2013:S1542-3565(13)01042-2. [PMID: 23891919 DOI: 10.1016/j.cgh.2013.04.051] [Reference Citation Analysis]
420 Malik TA, Manne A, Oster RA, Eckhoff A, Inusah S, Gutierrez AM. Obesity is Associated With Poor Surgical Outcome in Crohn's Disease. Gastroenterology Res 2013;6:85-90. [PMID: 27785234 DOI: 10.4021/gr553w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
421 Miyake Y, Hasebe A, Tanihira T, Shiraishi A, Imai Y, Tatsukawa H, Yamago H, Nakahara H, Shimizu Y, Ninomiya K, Hiraoka A, Miyata H, Ninomiya T, Michitaka K. Hepatitis B virus reactivation induced by infliximab administration in a patient with Crohn's disease. Case Reports Hepatol 2013;2013:461879. [PMID: 25374717 DOI: 10.1155/2013/461879] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
422 Sandborn WJ, Elliott DE, Weinstock J, Summers RW, Landry-Wheeler A, Silver N, Harnett MD, Hanauer SB. Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn’s disease. Aliment Pharmacol Ther. 2013;38:255-263. [PMID: 23730956 DOI: 10.1111/apt.12366] [Cited by in Crossref: 89] [Cited by in F6Publishing: 79] [Article Influence: 9.9] [Reference Citation Analysis]
423 Paparo F, Revelli M, Puppo C, Bacigalupo L, Garello I, Garlaschi A, Biscaldi E, Rollandi L, Binda GA, Rollandi GA. Crohn's disease recurrence in patients with ileocolic anastomosis: value of computed tomography enterography with water enema. Eur J Radiol 2013;82:e434-40. [PMID: 23727378 DOI: 10.1016/j.ejrad.2013.04.033] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
424 Cheifetz AS. Management of active Crohn disease. JAMA 2013;309:2150-8. [PMID: 23695484 DOI: 10.1001/jama.2013.4466] [Cited by in Crossref: 87] [Cited by in F6Publishing: 69] [Article Influence: 9.7] [Reference Citation Analysis]
425 Brown CL, Smith K, McCaughey L, Walker D. Colicin-like bacteriocins as novel therapeutic agents for the treatment of chronic biofilm-mediated infection. Biochem Soc Trans 2012;40:1549-52. [PMID: 23176515 DOI: 10.1042/BST20120241] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
426 Steenholdt C, Palarasah Y, Bendtzen K, Teisner A, Brynskov J, Teisner B, Nielsen CH. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2013;37:1172-83. [DOI: 10.1111/apt.12330] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
427 Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Naim A, Lofland JH. The Employee Absenteeism Costs of Inflammatory Bowel Disease: Evidence From US National Survey Data. Journal of Occupational & Environmental Medicine 2013;55:393-401. [DOI: 10.1097/jom.0b013e31827cba48] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
428 Mancuso A, Gentiluomo M, Vangeli M, Torre MD, Belli LS. Diarrhea as sole presentation of Good's syndrome mimicking Crohn's disease. Clinical Immunology 2013;147:9-10. [DOI: 10.1016/j.clim.2013.01.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
429 Bevan R, Rees CJ, Rutter MD, Macafee DAL. Review of the use of intralesional steroid injections in the management of ileocolonic Crohn's strictures. Frontline Gastroenterol 2013;4:238-43. [PMID: 28839732 DOI: 10.1136/flgastro-2012-100297] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
430 Sandborn WJ, Colombel JF, Panés J, Castillo M, Robinson AM, Zhou Q, Yang M, Thakkar R. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.J Crohns Colitis. 2013;7:958-967. [PMID: 23517933 DOI: 10.1016/j.crohns.2013.02.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
431 Rosenfeld G, Qian H, Bressler B. The risks of post-operative complications following pre-operative infliximab therapy for Crohn’s disease in patients undergoing abdominal surgery: a systematic review and meta-analysis. J Crohns Colitis. 2013;7:868-877. [PMID: 23466411 DOI: 10.1016/j.crohns.2013.01.019] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 7.9] [Reference Citation Analysis]
432 Peyrin-Biroulet L, Fiorino G, Buisson A, Danese S. First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol 2013;10:345-51. [PMID: 23458890 DOI: 10.1038/nrgastro.2013.31] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
433 Pai HH, Keyes M, Morris WJ, Christie J. Toxicity after 125I prostate brachytherapy in patients with inflammatory bowel disease. Brachytherapy 2013;12:126-33. [DOI: 10.1016/j.brachy.2012.04.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
434 Maggiori L, Panis Y. Surgical management of IBD--from an open to a laparoscopic approach. Nat Rev Gastroenterol Hepatol. 2013;10:297-306. [PMID: 23419288 DOI: 10.1038/nrgastro.2013.30] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
435 Nielsen OH, Bjerrum JT, Herfarth H, Rogler G. Recent advances using immunomodulators for inflammatory bowel disease. J Clin Pharmacol. 2013;53:575-588. [PMID: 23408468 DOI: 10.1002/jcph.2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
436 Bouguen G, Siproudhis L, Gizard E, Wallenhorst T, Billioud V, Bretagne JF, Bigard MA, Peyrin-Biroulet L. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab. Clin Gastroenterol Hepatol. 2013;11:975-81.e1-4. [PMID: 23376316 DOI: 10.1016/j.cgh.2012.12.042] [Cited by in Crossref: 122] [Cited by in F6Publishing: 112] [Article Influence: 13.6] [Reference Citation Analysis]
437 Calabrese E, Zorzi F, Onali S, Stasi E, Fiori R, Prencipe S, Bella A, Petruzziello C, Condino G, Lolli E, Simonetti G, Biancone L, Pallone F. Accuracy of small-intestine contrast ultrasonography, compared with computed tomography enteroclysis, in characterizing lesions in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2013;11:950-955. [PMID: 23375998 DOI: 10.1016/j.cgh.2013.01.015] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
438 Herfarth HH, Long MD, Isaacs KL. Methotrexate: underused and ignored? Dig Dis 2012;30 Suppl 3:112-8. [PMID: 23295701 DOI: 10.1159/000342735] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
439 Lee YS, Baek SH, Kim MJ, Lee YM, Lee Y, Choe YH. Efficacy of early infliximab treatment for pediatric Crohn's disease: A three-year follow-up. Pediatr Gastroenterol Hepatol Nutr. 2012;15:243-249. [PMID: 24010094 DOI: 10.5223/pghn.2012.15.4.243] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
440 Pinto N, Cohn SL, Dolan ME. Using germline genomics to individualize pediatric cancer treatments. Clin Cancer Res 2012;18:2791-800. [PMID: 22589487 DOI: 10.1158/1078-0432.CCR-11-1938] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
441 Corrigan A, Arenas-Hernandez M, Blaker P, Sanderson J, Marinaki A. Let's get personal: predicting thiopurine and fluoropyrimidine toxicity. Per Med 2012;9:859-70. [PMID: 29776234 DOI: 10.2217/pme.12.91] [Reference Citation Analysis]
442 Zhang S, Li R, Qing Q, Zhang T, Zhou Y, Chen Y, Zhang Y, Lin S, Liu Y; Cochrane IBD Group. Anti-IL-17 monoclonal antibody for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd010147] [Reference Citation Analysis]
443 Hou JK, Kramer JR, Richardson P, Sansgiry S, El-Serag HB. Myelosuppression monitoring after immunomodulator initiation in veterans with inflammatory bowel disease: a national practice audit. Aliment Pharmacol Ther 2012;36:1049-56. [PMID: 23061548 DOI: 10.1111/apt.12075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
444 Patil SA, Rustgi A, Langenberg P, Cross RK. Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice. Dig Dis Sci 2013;58:209-15. [PMID: 23014844 DOI: 10.1007/s10620-012-2323-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
445 Parmar KR, Patel E, McCann P. A likely diagnosis of Crohn's disease in a 95-year-old woman. BMJ Case Rep 2012;2012:bcr2012006445. [PMID: 23001095 DOI: 10.1136/bcr-2012-006445] [Reference Citation Analysis]
446 Otley A, Leleiko N, Langton C, Lerer T, Mack D, Evans J, Pfefferkorn M, Carvalho R, Rosh J, Griffiths A, Oliva-hemker M, Kay M, Bousvaros A, Stephens M, Samson C, Grossman A, Keljo D, Markowitz J, Hyams J. Budesonide Use in Pediatric Crohn Disease. Journal of Pediatric Gastroenterology & Nutrition 2012;55:200-4. [DOI: 10.1097/mpg.0b013e31824a09c2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
447 Panaccione R, Hibi T, Peyrin-Biroulet L, Schreiber S. Implementing changes in clinical practice to improve the management of Crohn’s disease. J Crohns Colitis. 2012;6 Suppl 2:S235-S242. [PMID: 22463930 DOI: 10.1016/s1873-9946(12)60503-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
448 Ye BD, Yang SK, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim YH, Lee H. [Guidelines for the management of Crohn’s disease]. Korean J Gastroenterol. 2012;59:141-179. [PMID: 22387837 DOI: 10.4166/kjg.2012.59.2.141] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
449 Norton BA, Thomas R, Lomax KG, Dudley-Brown S. Patient perspectives on the impact of Crohn's disease: results from group interviews. Patient Prefer Adherence 2012;6:509-20. [PMID: 22879737 DOI: 10.2147/PPA.S32690] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
450 Wenzl HH. Diarrhea in chronic inflammatory bowel diseases. Gastroenterol Clin North Am 2012;41:651-75. [PMID: 22917170 DOI: 10.1016/j.gtc.2012.06.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
451 Weizman AV, Silverberg MS. Have genomic discoveries in inflammatory bowel disease translated into clinical progress? Curr Gastroenterol Rep. 2012;14:139-145. [PMID: 22302508 DOI: 10.1007/s11894-012-0248-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
452 Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Lofland JH. Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey. Dig Dis Sci. 2012;57:3080-3091. [PMID: 22790905 DOI: 10.1007/s10620-012-2289-y] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 6.1] [Reference Citation Analysis]
453 Pineton de Chambrun GP, Torres J, Darfeuille-Michaud A, Colombel JF. The role of anti(myco)bacterial interventions in the management of IBD: is there evidence at all? Dig Dis. 2012;30:358-367. [PMID: 22796797 DOI: 10.1159/000338126] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
454 Mohabbat AB, Sandborn WJ, Loftus EV, Wiesner RH, Bruining DH. Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients. Aliment Pharmacol Ther. 2012;36:569-574. [PMID: 22779779 DOI: 10.1111/j.1365-2036.2012.05217.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 4.5] [Reference Citation Analysis]
455 Suzuki Y, Motoya S, Takazoe M, Kosaka T, Date M, Nii M, Hibi T. Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study. J Crohns Colitis. 2013;7:239-247. [PMID: 22766525 DOI: 10.1016/j.crohns.2012.06.006] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
456 Cascio A, Iaria C, Ruggeri P, Fries W. Cytomegalovirus pneumonia in patients with inflammatory bowel disease: a systematic review. International Journal of Infectious Diseases 2012;16:e474-9. [DOI: 10.1016/j.ijid.2012.03.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
457 Bessissow T, Renard M, Hoffman I, Vermeire S, Rutgeerts P, Van Assche G. Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. Aliment Pharmacol Ther 2012;36:312-23. [PMID: 22725726 DOI: 10.1111/j.1365-2036.2012.05189.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 49] [Article Influence: 6.0] [Reference Citation Analysis]
458 Alhagamhmad MH, Day AS, Lemberg DA, Leach ST. An update of the role of nutritional therapy in the management of Crohn’s disease. J Gastroenterol. 2012;47:872-882. [PMID: 22699323 DOI: 10.1007/s00535-012-0617-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
459 Carter CT, Waters HC, Smith DB. Effect of a continuous measure of adherence with infliximab maintenance treatment on inpatient outcomes in Crohn's disease. Patient Prefer Adherence 2012;6:417-26. [PMID: 22723726 DOI: 10.2147/PPA.S31115] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
460 Despott EJ, Fraser C. Small bowel endoscopy in inflammatory bowel disease. Best Practice & Research Clinical Gastroenterology 2012;26:279-91. [DOI: 10.1016/j.bpg.2012.01.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
461 Desales AL, Mendez-navarro J, Méndez-tovar LJ, Ortiz-olvera NX, Cullen G, Ocampo J, Lemus W, Tun AE, Mayoral-zavala A, Dehesa-violante M. Pneumocystosis in a patient with Crohn's disease treated with combination therapy with adalimumab. Journal of Crohn's and Colitis 2012;6:483-7. [DOI: 10.1016/j.crohns.2011.10.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
462 Maggiori L, Michelassi F. How I Do It: Side-to-Side Isoperistaltic Strictureplasty for Extensive Crohn’s Disease. J Gastrointest Surg 2012;16:1976-80. [DOI: 10.1007/s11605-012-1891-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
463 Tang DH, Armstrong EP, Lee JK. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease. Pharmacotherapy 2012;32:515-26. [PMID: 22528603 DOI: 10.1002/j.1875-9114.2011.01053.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
464 Hovde &, Moum BA. Epidemiology and clinical course of Crohn's disease: Results from observational studies. World J Gastroenterol 2012; 18(15): 1723-1731 [PMID: 22553396 DOI: 10.3748/wjg.v18.i15.1723] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 64] [Article Influence: 8.2] [Reference Citation Analysis]
465 Blonski W, Buchner AM, Lichtenstein GR. Patient adherence and efficacy of certolizumab pegol in the management of Crohn's disease. Clin Med Insights Gastroenterol 2012;5:11-21. [PMID: 24833930 DOI: 10.4137/CGast.S7613] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
466 Suzuki S, Takai-Igarashi T, Fukuoka Y, Wall DP, Tanaka H, Tonellato PJ. Systems analysis of inflammatory bowel disease based on comprehensive gene information. BMC Med Genet 2012;13:25. [PMID: 22480395 DOI: 10.1186/1471-2350-13-25] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
467 Louis E, Löfberg R, Reinisch W, Camez A, Yang M, Pollack PF, Chen N, Chao J, Mulani PM. Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial. J Crohns Colitis 2013;7:34-43. [PMID: 22480772 DOI: 10.1016/j.crohns.2012.02.017] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
468 Roy D, Snowden A. Concordance in action: case study of medication management. Nurse Prescribing 2012;10:195-200. [DOI: 10.12968/npre.2012.10.4.195] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
469 Lin Z, Bai Y, Zheng P. Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn's disease. Eur J Gastroenterol Hepatol. 2011;23:1100-1110. [PMID: 21971373 DOI: 10.1097/MEG.0b013e32834b9544] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
470 Rubin DT, Uluscu O, Sederman R. Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data. Inflamm Bowel Dis 2012;18:2225-31. [PMID: 22359399 DOI: 10.1002/ibd.22925] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 5.6] [Reference Citation Analysis]
471 Ha C, Ullman TA, Siegel CA, Kornbluth A. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol. 2012;10:1002-7; quiz e78. [PMID: 22343692 DOI: 10.1016/j.cgh.2012.02.004] [Cited by in Crossref: 184] [Cited by in F6Publishing: 170] [Article Influence: 18.4] [Reference Citation Analysis]
472 Ferrante M, Karmiris K, Newnham E, Siffledeen J, Zelinkova Z, van Assche G, Lakatos PL, Panés J, Sturm A, Travis S, van der Woude CJ, Reinisch W, Colombel J, Panaccione R. Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: Results from an international survey and discussion programme. Journal of Crohn's and Colitis 2012;6:116-31. [DOI: 10.1016/j.crohns.2011.09.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
473 Shahidi N, Fu YT, Qian H, Bressler B. Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18:2034-2042. [PMID: 22294550 DOI: 10.1002/ibd.22901] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 4.8] [Reference Citation Analysis]
474 Buchner AM, Blonski W, Lichtenstein GR. Update on the management of Crohn‘s disease. Curr Gastroenterol Rep. 2011;13:465-474. [PMID: 21792543 DOI: 10.1007/s11894-011-0220-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
475 Mack DE, Wilson PM, Gilmore JC, Gunnell KE. Leisure-time physical activity in Canadians living with Crohn disease and ulcerative colitis: population-based estimates. Gastroenterol Nurs. 2011;34:288-294. [PMID: 21814062 DOI: 10.1097/sga.0b013e3182248732] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
476 Smith P, Siddharth J, Pearson R, Holway N, Shaxted M, Butler M, Clark N, Jamontt J, Watson RP, Sanmugalingam D, Parkinson SJ. Host genetics and environmental factors regulate ecological succession of the mouse colon tissue-associated microbiota. PLoS One. 2012;7:e30273. [PMID: 22272321 DOI: 10.1371/journal.pone.0030273] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
477 Ye BD, Yang S, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim Y, Lee H; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Guidelines for the Management of Crohn's Disease. Intest Res 2012;10:26. [DOI: 10.5217/ir.2012.10.1.26] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
478 Allen JI. Gastroenterologists and the Triple Aim: How to Become Accountable. Gastrointestinal Endoscopy Clinics of North America 2012;22:85-96. [DOI: 10.1016/j.giec.2011.08.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
479 Blonski W, Buchner AM, Lichtenstein GR. Inflammatory bowel disease therapy: current state-of-the-art. Curr Opin Gastroenterol 2011;27:346-57. [PMID: 21654383 DOI: 10.1097/MOG.0b013e328347aef3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
480 Binion DG, Louis E, Oldenburg B, Mulani P, Bensimon AG, Yang M, Chao J. Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: a meta-analysis. Can J Gastroenterol 2011;25:492-6. [PMID: 21912760 DOI: 10.1155/2011/938194] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
481 Costantino G, Furfaro F, Belvedere A, Alibrandi A, Fries W. Thiopurine treatment in inflammatory bowel disease: response predictors, safety, and withdrawal in follow-up. J Crohns Colitis. 2012;6:588-596. [PMID: 22398045 DOI: 10.1016/j.crohns.2011.11.007] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
482 Maharshak N, Plevy SE. A Crohn's Disease Patient Who Does Not Respond to Infliximab: What Is Next? Clinical Gastroenterology and Hepatology 2011;9:1033-8. [DOI: 10.1016/j.cgh.2011.05.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
483 Schreiber S. Certolizumab pegol for the treatment of Crohn's disease. Therap Adv Gastroenterol 2011;4:375-89. [PMID: 22043230 DOI: 10.1177/1756283X11413315] [Cited by in Crossref: 35] [Cited by in F6Publishing: 42] [Article Influence: 3.2] [Reference Citation Analysis]
484 Brown AC, Rampertab SD, Mullin GE. Existing dietary guidelines for Crohn's disease and ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2011;5:411-425. [PMID: 21651358 DOI: 10.1586/egh.11.29] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 5.5] [Reference Citation Analysis]
485 Bradford K, Shih DQ. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J Gastroenterol 2011; 17(37): 4166-4173 [PMID: 22072847 DOI: 10.3748/wjg.v17.i37.4166] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 44] [Article Influence: 4.2] [Reference Citation Analysis]
486 Kumar A, Auron M, Aneja A, Mohr F, Jain A, Shen B. Inflammatory bowel disease: perioperative pharmacological considerations. Mayo Clin Proc. 2011;86:748-757. [PMID: 21803957 DOI: 10.4065/mcp.2011.0074] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
487 Vaughn BP, Doherty GA, Gautam S, Moss AC, Cheifetz AS. Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. Inflamm Bowel Dis. 2012;18:1057-1063. [PMID: 21953829 DOI: 10.1002/ibd.21824] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
488 Doherty GA, Miksad RA, Cheifetz AS, Moss AC. Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn’s disease. Inflamm Bowel Dis. 2012;18:1608-1616. [PMID: 21905173 DOI: 10.1002/ibd.21904] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
489 Barrett M, Chandra SB. A review of major Crohn’s disease susceptibility genes and their role in disease pathogenesis. Genes Genom 2011;33:317-25. [DOI: 10.1007/s13258-011-0076-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
490 Gupta NK, Thaker AI, Kanuri N, Riehl TE, Rowley CW, Stenson WF, Ciorba MA. Serum analysis of tryptophan catabolism pathway: correlation with Crohn’s disease activity. Inflamm Bowel Dis. 2012;18:1214-1220. [PMID: 21823214 DOI: 10.1002/ibd.21849] [Cited by in Crossref: 75] [Cited by in F6Publishing: 78] [Article Influence: 6.8] [Reference Citation Analysis]
491 Guidi L, Pugliese D, Armuzzi A. Update on the management of inflammatory bowel disease: specific role of adalimumab. Clin Exp Gastroenterol. 2011;4:163-172. [PMID: 21904462 DOI: 10.2147/ceg.s14558] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
492 Edula RG, Picco MF. An evidence-based review of natalizumab therapy in the management of Crohn's disease. Ther Clin Risk Manag 2009;5:935-42. [PMID: 20011247 DOI: 10.2147/tcrm.s5550] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
493 Val JHD. Old-age inflammatory bowel disease onset: A different problem? World J Gastroenterol 2011; 17(22): 2734-2739 [PMID: 21734781 DOI: 10.3748/wjg.v17.i22.2734] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
494 Tamboli CP, Doman DB, Patel A. Current and future role of biomarkers in Crohn’s disease risk assessment and treatment. Clin Exp Gastroenterol. 2011;4:127-140. [PMID: 21753895 DOI: 10.2147/ceg.s18187] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
495 Woolf RT, Smith CH. How genetic variation affects patient response and outcome to therapy for psoriasis. Expert Rev Clin Immunol 2010;6:957-66. [PMID: 20979559 DOI: 10.1586/eci.10.74] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
496 Farkas H, Csuka D, Gács J, Czaller I, Zotter Z, Füst G, Varga L, Gergely P. Lack of increased prevalence of immunoregulatory disorders in hereditary angioedema due to C1-inhibitor deficiency. Clin Immunol 2011;141:58-66. [PMID: 21636327 DOI: 10.1016/j.clim.2011.05.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
497 Sandborn WJ, Schreiber S, Feagan BG, Rutgeerts P, Younes ZH, Bloomfield R, Coteur G, Guzman JP, D'Haens GR. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 2011;9:670-678.e3. [PMID: 21642014 DOI: 10.1016/j.cgh.2011.04.031] [Cited by in Crossref: 106] [Cited by in F6Publishing: 103] [Article Influence: 9.6] [Reference Citation Analysis]
498 Holtmeier W, Zeuzem S, Preiss J, Kruis W, Böhm S, Maaser C, Raedler A, Schmidt C, Schnitker J, Schwarz J. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn’s disease: good safety profile but lack of efficacy. Inflamm Bowel Dis. 2011;17:573-582. [PMID: 20848527 DOI: 10.1002/ibd.21345] [Cited by in Crossref: 61] [Cited by in F6Publishing: 43] [Article Influence: 5.5] [Reference Citation Analysis]
499 Burger D, Travis S. Conventional Medical Management of Inflammatory Bowel Disease. Gastroenterology 2011;140:1827-1837.e2. [DOI: 10.1053/j.gastro.2011.02.045] [Cited by in Crossref: 135] [Cited by in F6Publishing: 129] [Article Influence: 12.3] [Reference Citation Analysis]
500 Hong IS, Ipema HJ, Gabay MP, Lodolce AE. Medication Repurposing: New Uses for Old Drugs. Journal of Pharmacy Technology 2011;27:132-40. [DOI: 10.1177/875512251102700306] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
501 Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, Kane SV, Sandborn WJ, Ullman TA, Moayyedi P. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011;106 Suppl 1:S2-S25; quiz S26. [PMID: 21472012 DOI: 10.1038/ajg.2011.58] [Cited by in Crossref: 177] [Cited by in F6Publishing: 170] [Article Influence: 16.1] [Reference Citation Analysis]
502 Doherty GA, Moss AC, Cheifetz AS. Capsule endoscopy for small-bowel evaluation in Crohn's disease. Gastrointest Endosc. 2011;74:167-175. [PMID: 21497806 DOI: 10.1016/j.gie.2011.01.067] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
503 Feagan BG, Hanauer SB, Coteur G, Schreiber S. Evaluation of a daily practice composite score for the assessment of Crohn’s disease: the treatment impact of certolizumab pegol: Composite score for certolizumab pegol response in Crohn’s disease. Alimentary Pharmacology & Therapeutics 2011;33:1143-51. [DOI: 10.1111/j.1365-2036.2011.04636.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
504 Bielig H, Velder J, Saiai A, Menning M, Meemboor S, Kalka-Moll W, Krönke M, Schmalz HG, Kufer TA. Anti-inflammatory arene--chromium complexes acting as specific inhibitors of NOD2 signalling. ChemMedChem 2010;5:2065-71. [PMID: 20973121 DOI: 10.1002/cmdc.201000320] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
505 Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106:630-642. [PMID: 21407186 DOI: 10.1038/ajg.2011.64] [Cited by in Crossref: 160] [Cited by in F6Publishing: 159] [Article Influence: 14.5] [Reference Citation Analysis]
506 Smith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, Zagon IS. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn’s disease: a randomized placebo-controlled trial. Dig Dis Sci. 2011;56:2088-2097. [PMID: 21380937 DOI: 10.1007/s10620-011-1653-7] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 6.6] [Reference Citation Analysis]
507 Hanauer SB, Kornbluth AA, Messick J, Rubin DT, Sandborn WJ, Sands BE. Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010;16 Suppl 1:S1-S11. [PMID: 21104734 DOI: 10.1002/ibd.21529] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
508 Peyrin-biroulet L, Lémann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease: Review: remission rates in IBD. Alimentary Pharmacology & Therapeutics 2011;33:870-9. [DOI: 10.1111/j.1365-2036.2011.04599.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 103] [Article Influence: 10.5] [Reference Citation Analysis]
509 Danese S, Colombel JF, Reinisch W, Rutgeerts PJ. Review article: infliximab for Crohn's disease treatment--shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther 2011;33:857-69. [PMID: 21320139 DOI: 10.1111/j.1365-2036.2011.04598.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 5.3] [Reference Citation Analysis]
510 Lee TW, Fedorak RN. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology. Gastroenterol Clin North Am. 2010;39:543-557. [PMID: 20951917 DOI: 10.1016/j.gtc.2010.08.018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
511 Bi X, Walsh A, Mahadevan-Jansen A, Herline A. Development of spectral markers for the discrimination of ulcerative colitis and Crohn’s disease using Raman spectroscopy. Dis Colon Rectum. 2011;54:48-53. [PMID: 21160313 DOI: 10.1007/dcr.0b013e3181fcf68d] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
512 Feagan BG, Sandborn WJ, Wolf DC, Coteur G, Purcaru O, Brabant Y, Rutgeerts PJ. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab: Randomised clinical trial: certolizumab health outcome in Crohn’s disease. Alimentary Pharmacology & Therapeutics 2011;33:541-50. [DOI: 10.1111/j.1365-2036.2010.04568.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
513 Ng SC, Chan FKL, Sung JJY. Review article: the role of non-biological drugs in refractory inflammatory bowel disease: Review: refractory inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 2011;33:417-27. [DOI: 10.1111/j.1365-2036.2010.04541.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
514 Fiorino G, Bonifacio C, Peyrin-Biroulet L, Minuti F, Repici A, Spinelli A, Fries W, Balzarini L, Montorsi M, Malesci A. Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn’s disease. Inflamm Bowel Dis. 2011;17:1073-1080. [PMID: 21484958 DOI: 10.1002/ibd.21533] [Cited by in Crossref: 162] [Cited by in F6Publishing: 141] [Article Influence: 13.5] [Reference Citation Analysis]
515 Tremaine WJ. Crohn's disease of the ileal pouch 16 years after proctocolectomy for ulcerative colitis. Clin Gastroenterol Hepatol 2011;9:198-201. [PMID: 21056695 DOI: 10.1016/j.cgh.2010.10.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
516 Bickston SJ, Muniyappa K. Natalizumab for the treatment of Crohn's disease. Expert Rev Clin Immunol. 2010;6:513-519. [PMID: 20594122 DOI: 10.1586/eci.10.38] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
517 Sankaran-Walters S, Ransibrahmanakul K, Grishina I, Hung J, Martinez E, Prindiville T, Dandekar S. Epstein-Barr virus replication linked to B cell proliferation in inflamed areas of colonic mucosa of patients with inflammatory bowel disease. J Clin Virol. 2011;50:31-36. [PMID: 21035384 DOI: 10.1016/j.jcv.2010.09.011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
518 Kane S. Preparing the Patient for Immunosuppressive Therapy. Curr Gastroenterol Rep 2010;12:502-6. [DOI: 10.1007/s11894-010-0142-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
519 Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, Yu AP, Cardoso AT, Chao J, Mulani PM. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy. Aliment Pharmacol Ther. 2010;32:1228-1239. [PMID: 20955442 DOI: 10.1111/j.1365-2036.2010.04466.x] [Cited by in Crossref: 112] [Cited by in F6Publishing: 102] [Article Influence: 9.3] [Reference Citation Analysis]
520 Nasir BS, Dozois EJ, Cima RR, Pemberton JH, Wolff BG, Sandborn WJ, Loftus EV, Larson DW. Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn’s disease. J Gastrointest Surg. 2010;14:1859-1865; discussion 1865-1866. [PMID: 20872084 DOI: 10.1007/s11605-010-1341-5] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 6.4] [Reference Citation Analysis]
521 Feagins LA, Spechler SJ. Biologic Agent Use Varies Inversely with Age at Diagnosis in Crohn’s Disease. Dig Dis Sci 2010;55:3164-70. [DOI: 10.1007/s10620-010-1397-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
522 Arai R. Serologic markers: impact on early diagnosis and disease stratification in inflammatory bowel disease. Postgrad Med. 2010;122:177-185. [PMID: 20675980 DOI: 10.3810/pgm.2010.07.2184] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
523 Ford AC, Khan KJ, Talley NJ, Moayyedi P. 5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis. Am J Gastroenterol 2011;106:413-20. [PMID: 20717106 DOI: 10.1038/ajg.2010.317] [Cited by in Crossref: 75] [Cited by in F6Publishing: 57] [Article Influence: 6.3] [Reference Citation Analysis]
524 Figueiredo P, Almeida N, Lopes S, Duque G, Freire P, Lérias C, Gouveia H, Sofia C. Small-bowel capsule endoscopy in patients with suspected Crohn’s disease-diagnostic value and complications. Diagn Ther Endosc. 2010;2010:101284. [PMID: 20811612 DOI: 10.1155/2010/101284] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
525 Eshuis EJ, Stokkers PC, Bemelman WA. Decision-making in ileocecal Crohn's disease management: surgery versus pharmacotherapy. Expert Rev Gastroenterol Hepatol 2010;4:181-9. [PMID: 20350265 DOI: 10.1586/egh.10.3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
526 Lin MV, Blonski W, Lichtenstein GR. What is the optimal therapy for Crohn‘s disease: step-up or top-down? Expert Rev Gastroenterol Hepatol. 2010;4:167-180. [PMID: 20350264 DOI: 10.1586/egh.10.4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
527 Juillerat P, Pittet V, Mottet C, Felley C, Gonvers J, Vader J, Burnand B, Froehlich F, Wolters FL, Stockbrügger RW, Michetti P; the EC-IBD Group. Appropriateness of early management of newly diagnosed Crohn's disease in a European population-based cohort. Scandinavian Journal of Gastroenterology 2010;45:1449-56. [DOI: 10.3109/00365521.2010.505660] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
528 Chiba M, Abe T, Tsuda H, Sugawara T, Tsuda S, Tozawa H, Fujiwara K, Imai H. Lifestyle-related disease in Crohn’s disease: Relapse prevention by a semi-vegetarian diet. World J Gastroenterol 2010; 16(20): 2484-2495 [PMID: 20503448 DOI: 10.3748/wjg.v16.i20.2484] [Cited by in CrossRef: 128] [Cited by in F6Publishing: 120] [Article Influence: 10.7] [Reference Citation Analysis]
529 Bultman E, Kuipers EJ, Van Der Woude CJ. Systematic review: steroid withdrawal in anti-TNF-treated patients with inflammatory bowel disease: Systematic review: steroid withdrawal during anti-TNF treatment. Alimentary Pharmacology & Therapeutics 2010;32:313-23. [DOI: 10.1111/j.1365-2036.2010.04373.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
530 Arai R. Therapy Adherence in Crohn's Disease: An Adult Case Study. Case Rep Gastroenterol 2010;4:153-7. [PMID: 20805937 DOI: 10.1159/000314230] [Reference Citation Analysis]
531 Sandborn WJ, Abreu MT, D’Haens G, Colombel JF, Vermeire S, Mitchev K, Jamoul C, Fedorak RN, Spehlmann ME, Wolf DC. Certolizumab pegol in patients with moderate to severe Crohn’s disease and secondary failure to infliximab. Clin Gastroenterol Hepatol. 2010;8:688-695.e2. [PMID: 20451663 DOI: 10.1016/j.cgh.2010.04.021] [Cited by in Crossref: 106] [Cited by in F6Publishing: 92] [Article Influence: 8.8] [Reference Citation Analysis]
532 Oussalah A, Chevaux JB, Fay R, Sandborn WJ, Bigard MA, Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol. 2010;105:1142-1149. [PMID: 20389296 DOI: 10.1038/ajg.2010.158] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 5.8] [Reference Citation Analysis]
533 Panaccione R, Colombel JF, Sandborn WJ, Rutgeerts P, D’Haens GR, Robinson AM, Chao J, Mulani PM, Pollack PF. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease. Aliment Pharmacol Ther. 2010;31:1296-1309. [PMID: 20298496 DOI: 10.1111/j.1365-2036.2010.04304.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 5.9] [Reference Citation Analysis]
534 Stephansson O, Larsson H, Pedersen L, Kieler H, Granath F, Ludvigsson JF, Falconer H, Ekbom A, Sørensen HT, Nørgaard M. Crohn's disease is a risk factor for preterm birth. Clin Gastroenterol Hepatol. 2010;8:509-515. [PMID: 20202483 DOI: 10.1016/j.cgh.2010.02.014] [Cited by in Crossref: 82] [Cited by in F6Publishing: 81] [Article Influence: 6.8] [Reference Citation Analysis]
535 Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Gastroenterol Clin North Am. 2009;38:577-594. [PMID: 19913203 DOI: 10.1016/j.gtc.2009.07.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
536 Seow CH, de Silva S, Kaplan GG, Devlin SM, Ghosh S, Panaccione R. Managing the risks of IBD therapy. Curr Gastroenterol Rep 2009;11:509-17. [PMID: 19903428 DOI: 10.1007/s11894-009-0077-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
537 Camilleri M, Parke DW. Perspective: Conflict of Interest and Professional Organizations: Considerations and Recommendations: . Academic Medicine 2010;85:85-91. [DOI: 10.1097/acm.0b013e3181c46429] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
538 Abraham BP, Thirumurthi S. Clinical significance of inflammatory markers. Curr Gastroenterol Rep 2009;11:360-7. [PMID: 19765363 DOI: 10.1007/s11894-009-0055-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
539 Leighton JA, Gralnek IM, Richner RE, Lacey MJ, Papatheofanis FJ. Capsule endoscopy in suspected small bowel Crohn’s disease: Economic impact of disease diagnosis and treatment. World J Gastroenterol 2009; 15(45): 5685-5692 [PMID: 19960565 DOI: 10.3748/wjg.15.5685] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
540 Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Med Clin North Am. 2010;94:1-18. [PMID: 19944795 DOI: 10.1016/j.mcna.2009.08.017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
541 Feagins LA, Cryer BL. Do Non-steroidal Anti-inflammatory Drugs Cause Exacerbations of Inflammatory Bowel Disease? Dig Dis Sci 2010;55:226-32. [DOI: 10.1007/s10620-009-1042-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
542 Picco MF, Cangemi JR. Inflammatory bowel disease in the elderly. Gastroenterol Clin North Am 2009;38:447-62. [PMID: 19699407 DOI: 10.1016/j.gtc.2009.06.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
543 Rivkin A. Certolizumab pegol for the management of Crohn’s disease in adults. Clin Ther. 2009;31:1158-1176. [PMID: 19695385 DOI: 10.1016/j.clinthera.2009.06.015] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
544 Oussalah A, Roblin X, Laharie D, Filippi J, Flamant M, Faure P, Phelip J, Bigard M, Peyrin-biroulet L. Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey. Alimentary Pharmacology & Therapeutics 2009;30:854-63. [DOI: 10.1111/j.1365-2036.2009.4097.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
545 Kotze LMDS, Rodrigues APB, Kotze LR, Nisihara RM. A Brazilian experience of the self transglutaminase-based test for celiac disease case finding and diet monitoring. World J Gastroenterol 2009; 15(35): 4423-4428 [PMID: 19764094 DOI: 10.3748/wjg.15.4423] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]